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Abstract
Printed educational materials (PEMs) have long been used as a tool for knowledge translation
despite the conflicting evidence surrounding their effectiveness. A pragmatic, 2x2 factorial,
cluster-randomized controlled trial was designed to ascertain the effectiveness of two distinct
formats of a PEM (insert and outsert) at improving adherence to guideline recommendations for
the management of diabetes complications among Ontario family and general practitioners.
Administrative databases were used to compare patient’s treatment regimens at baseline and one
year following PEM mailout to determine whether prescription rates intensified in response to
the PEMs. A total of 4,118 practices (4,957 physicians) and 185,454 patients were included.
Intensification rates in the four groups were similar and approximately equal to 46%. In
intention-to-treat analyses, no treatment effect was found with the insert (OR 0.99, 95% CI 0.96
to 1.02), nor with the outsert (OR 1.01, 95% CI 0.98 to 1.04). Thus, PEMs were not effective at
improving physician’s adherence to guidelines for diabetes care.

Keywords
Printed educational materials, cluster randomized controlled trial, pragmatic, knowledge
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Summary for Lay Audience
Despite numerous medical breakthroughs, the health status of Ontarians is far from perfect. This
disconnect is, in part, due to the poor translation of research findings from the bench to the
bedside. To address this problem, many studies have investigated different strategies to bridge
the gap between researchers and front-line staff. Printed educational materials (PEMs) consist of
any recommendation for clinical care, whether it be a journal article, a magazine insert, or a
letter that is delivered in print format to the recipient. PEMs have long been used as a strategy to
inform clinicians on evidence-based practices and to persuade them to use these treatments or
interventions. However, the literature provides conflicting evidence surrounding the
effectiveness of PEMs, yet they continue to be used today. Thus, the present study aimed to
investigate the effectiveness of PEMs at changing provider behavior.

The Ontario Printed Educational Message (OPEM) trial was carried out in 2005, a time when the
prescription rate of drugs used to prevent diabetic complications was well below guideline
recommendations. PEMs were thus developed to highlight several evidence-based
recommendations for drug use among individuals with diabetes, and Ontario family and general
practitioners’ practices were allocated at random to receive one of two formats of the resulting
PEM (a post card sized message or a long article, referred to as the outsert and insert,
respectively), both, or neither (as a usual situation comparison group). Health administrative
databases were used to ascertain the effectiveness of PEMs by observing whether treatment
intensification occurred to a greater degree among patients of physicians who received a PEM,
compared to those who did not.
Neither the insert nor the outsert were successful at causing physicians to intensify their patient’s
treatment regimen by adding a new drug, increasing the dose of a current drug, or switching from
one drug to another drug.
Thus, the use of PEMs to improve physician’s adherence to guideline recommendations for
diabetes care is ineffective and should not be encouraged. Further research is required to
investigate other strategies to inform physicians on evidence-based recommendations, as
prescriptions for diabetes care remain below standard today.
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Chapter 1
1 Introduction
This chapter begins with a brief introduction to the thesis and the main topics to be covered in
section 1.1. The study rationale is then discussed in section 1.2, followed by the objectives and
hypotheses in section 1.3. The role of the student is highlighted in section 1.4. The last section,
1.5, describes the format of the thesis.

1.1 Overview
Investing in health research alone does relatively little to improve patient outcomes unless
sufficient effort and resources are allocated to ensure that the information is communicated
effectively to the relevant parties and changes their practice to conform to the evidence. The
Government of Canada’s commitment to improving the health of their citizens through research
efforts is pronounced. In fact, since 2000, the Canadian Institutes of Health Research, Canada’s
research investment agency, has invested over $14 billion into health research (Canadian
Institute for Health Research, 2018). However, the health status of many Canadians continues to
be poor. In 2017, the Canadian Institute for Health Information measured physicians’ adherence
to selected guidelines, and found that up to 30% of the care that Canadians received was
potentially unnecessary and even harmful (Canadian Institute for Health Information, 2017).
This disconnect between health research and routine clinical practice is known as the evidenceto-practice gap, or the second translational gap, and continues to pose a threat to the health of
Canadians today (Lau et al., 2014).

Despite being a highly researched area for decades, the evidence-to-practice gap persists.
Researchers have quantified that it takes, on average, 17 years for research to be applied to
practice (Morris et al., 2011). As a result, clinicians continue to deliver care that has been proven
to be outdated, unnecessary, and even harmful for many years following the emergence of
research results (Grimshaw et al., 2012). Patients are therefore unable to benefit from advances
in healthcare and, consequently, experience a diminished quality of life (Grimshaw et al., 2012).
It is estimated that, to keep up with current medical research, general internists would be
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required to read 20 papers per day (Shaneyfelt, 2001). Balancing a heavy load of reading in
addition to seeing numerous patients per day is unrealistic, necessitating the development of
novel strategies to bridge this gap.

1.1.1 Knowledge translation
Knowledge translation (KT) is an emerging field focused on the activities required to move
research from the bench to the beside in attempts to attenuate the evidence-to-practice gap. The
overall aim is to enhance communication through all stages of research, starting from the
creation of knowledge to its application in routine care (Sudsawad, 2007). In essence, researchers
and clinicians must collaborate, rather than operating in two unconnected fields. For a KT
intervention to be successful, the following four steps must be completed: synthesis,
dissemination, exchange, and ethically-sound application of knowledge (Canadian Institute for
Health Research, 2016). KT interventions are classified into three categories: implementation
tools, resource planning tools, and evaluation tools (Moore et al., 2017). Among the extensively
researched interventions is audit and feedback. This KT strategy provides clinicians with
feedback on their performance to encourage them to address any gaps in their practice (Flottorp
et al., 2010). Moreover, local opinion leaders are credible, trustworthy and likeable individuals
who are tasked with delivering educational material to clinicians in attempts to eliminate
evidence-to-practice gaps (Flodgren et al., 2011). Another example of a commonly used KT
strategy is reminder systems (Grimshaw et al., 2012). Reminders, delivered via mail or
electronically, are used to prompt clinicians to engage in desirable behaviors or actions according
to best practices (Grimshaw et al., 2012). Researchers generally agree that active dissemination
of materials and multi-faceted interventions are superior to passive dissemination strategies.
Nonetheless, printed educational materials (PEMs), a passive dissemination strategy, have been
used extensively throughout the years in attempts to change physician practice. The wide-reach,
convenience, and low-cost associated with PEMs has led to their widespread use (Giguère et al.,
2012).

1.1.2 Printed educational materials
PEMs are defined as “the distribution of published or printed recommendations for clinical care”
(Johnson & May, 2015). Clinical recommendations come in a variety of forms, including clinical
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practice guidelines, email summaries, and journal articles (Grudniewicz et al., 2015a). To attract
the eye of the reader, PEMs must be designed and developed with careful consideration and
substantial detail. Including too much detail, or too few details, may prevent the uptake of the
PEM. Researchers have suggested that many characteristics, such as font size, color, use of
graphics and specificity influence the uptake of PEMs and should therefore be considered in the
design phase (Grudniewicz et al., 2015b). While the development and design of PEMs may be
time-consuming and costly, the costs associated with the distribution of PEMs, including printing
and mailing, are small and much lower than other KT interventions which have a costly human
component.

The value, convenience, and low cost of PEMs has led to their widespread use (Giguère et al.,
2012). However, the overall effectiveness of PEMs continues to be debated today. Numerous
systematic reviews have attempted to provide a formal recommendation for the use of PEMs as a
behaviour change strategy aimed at physicians, but the flaws in the available literature
compromise the quality of their conclusions (Grudniewicz et al., 2015a). A 1998 systematic
review concluded that passive dissemination strategies are generally ineffective, and, when they
do alter practice, the effect is negligible (Bero et al., 1998). This conclusion failed to dissuade
researchers from using PEMs, as evident by the large number of primary research articles
investigating the effectiveness of PEMs in recent years. A large review conducted in 2004 found
a modest improvement in guideline dissemination with the use of PEMs (Grimshaw et al., 2004).
With a more explicit analytical framework than previous reviews, the authors revealed that
PEMs resulted in a median absolute improvement in physician performance of 8.1% (range +3.6
to +17%), much larger than previously found (Grimshaw et al., 2004). The evidence has more
recently reversed again; the most recent review was undertaken in 2015 and revealed that, at
present, PEMs are ineffective at changing primary care physician (PCP) behaviors (Grudniewicz
et al., 2015a).

1.1.3 Diabetes mellitus
Despite being considered a “healthy nation”, Canada continues to fall short in one area: chronic
disease management (Government of Canada, 2019). In 2017, 89% of Canadian deaths were
attributed to non-communicable diseases such as cancers, cardiovascular diseases, and diabetes
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(Institute for Health Metrics and Evaluation, 2017). Diabetes mellitus, commonly referred to as
diabetes, is an example of a chronic disease that poses a large threat to the health of Canadians in
spite of many measures available for both the prevention and management of the disease.
Diabetes, in its most basic definition, is a disease characterized by chronically high blood sugar,
known as hyperglycemia. Hyperglycemia results from impairments associated with insulin
secretion, with insulin being a hormone responsible for regulating blood sugar levels, as well as
insulin resistance. The nature, and severity, of insulin impairment depends on the type of
diabetes. According to Diabetes Canada, diabetes can be classified into four categories: type 1
diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes, and “other”
diabetes (Diabetes Canada, 2018b). T1DM is the most severe form, characterized by insulin
deficiency due to the destruction of cells in the pancreas responsible for the production of insulin
(Diabetes Canada, 2018b). Individuals with T1DM are therefore unable to produce insulin,
resulting in the need for daily insulin administration (World Health Organization [WHO], 2018).
T2DM is characterized by the body’s inability to effectively use insulin due to insulin resistance,
or the inability to produce enough insulin due to relative insulin deficiency (WHO, 2018;
Diabetes Canada, 2018b). The treatment course for T2DM is less straightforward, as it depends
on the severity of the disease. While some individuals with T2DM are able to manage their
hyperglycemia with lifestyle changes, others require insulin therapy (WHO, 2018). Another form
of diabetes characterized by the inability to produce enough insulin is gestational diabetes.
Gestational diabetes is a temporary form of diabetes, characterized by glucose intolerance
induced by pregnancy (Diabetes Canada, 2018b). Despite being temporary, the onset of
gestational diabetes increases the likelihood of developing T2DM, and therefore represents a
serious health concern (WHO, 2018). The last categorization of diabetes, “other”, consists of
uncommon forms of the disease, such as specific genetically defined diabetes and drug induced
diabetes (Diabetes Canada, 2018b).

While diabetes manifests in different forms, the consequences are undifferentiated. Prolonged
hyperglycemia is associated with numerous long-term complications, including cardiovascular
disease (CVD), blindness, kidney disease, and non-traumatic amputation (Booth et al., 2012).
With CVD being the leading cause of morbidity and mortality among patients with diabetes, it is
essential that its risk factors be managed (Leon & Maddox, 2015). Many conditions, such as
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hypertension and high cholesterol, are common in individuals with diabetes and have been
shown to contribute to the development of CVD (Diabetes Canada, 2018b). The evidence for the
cardiovascular risk reduction abilities of antihypertensives and cholesterol-lowering agents for
individuals with diabetes is well documented (UK Prospective Diabetes Study Group, 1998b;
Heart Protection Study Collaborative Group, 2003). In fact, in 1998, it was shown that
aggressive blood pressure (BP) management resulted in significantly greater reductions in the
vascular complications associated with diabetes than did glucose-lowering agents (UK
Prospective Diabetes Study Group, 1998b). Thus, the need to adopt a multi-faceted treatment
approach, managing all risks associated with diabetes, rather than treating high blood glucose
alone, is clear.

As both the prevalence and the incidence of diabetes continue to increase, researchers consider
diabetes to be “one of the most costly and burdensome chronic diseases of our time” (Lipscone
& Hux, 2007). The WHO estimated that by 2030, the worldwide prevalence of diabetes would
rise to 6.4%, corresponding to a 60% and a 39% increase from 1995 and 2000, respectively
(Lipscone & Hux, 2007). This prediction was based on the assumption of a constant obesity rate
over the years; however, with current lifestyle and behaviour changes, this prediction is likely to
largely underestimate the true prevalence (Lipscone & Hux, 2007). In fact, between 1995 and
2005, the prevalence of diabetes in Ontario increased by 81.6%, surpassing the 39% predicted
increase, suggesting that the true prevalence in 2030 is likely to be much higher than anticipated
(Lipscone & Hux, 2007).

1.1.4 The Ontario printed educational messages programme
The Ontario printed educational message (OPEM) research programme consisted of a series of
three factorial cluster randomized controlled trials (cRCTs) aimed at investigating the
effectiveness of PEMs by addressing key gaps in primary care practice (Zwarenstein et al.,
2007). The trial was designed to be pragmatic to answer the question of effectiveness: does the
intervention work in real-world settings (Singal et al., 2014)? The programme was carried out
between 2004 and 2006, a time when hypertension and diabetes care were below standard
(Zwarenstein et al., 2007). Accordingly, the programme attempted to bridge the evidence-topractice gap in the following areas: retinal screening for patients with diabetes, the use of
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diuretics for hypertension, and prescription drug use for managing the complications associated
with diabetes (Zwarenstein et al., 2007). The research programme aimed to answer the following
questions: whether PEMs are effective at changing Ontario PCPs adherence to guidelines, if
different sized PEMs have a varying degree of effectiveness, and the ability of PEMs to close
gaps in the health care system (Zwarenstein et al., 2007). The PEMs were mailed to Ontario
family and general practitioners (FP/GPs) and came in three different forms: a short message, a
long message, or both (Zwarenstein et al., 2007). Administrative data held at ICES was used to
obtain baseline and outcome measures, and all physician- and patient-level characteristics. A
large proportion of trials conducted before the OPEM programme were small-scale and
encompassed numerous methodological and analytical flaws. This programme thus represented a
novel approach to studying the effectiveness of PEMs on a large scale by utilizing administrative
data to study multiple interventions at dramatically lower costs.

1.2 Rationale
The rising prevalence and incidence of diabetes in Ontario is worrisome to both individuals and
to public health officials. The lifestyle and behavioral trends that have contributed to the increase
in incidence do not appear to be changing, necessitating the development of strategies targeted at
improving the course of disease among those who are suffering. Despite numerous efforts, both
at the national and provincial level, the adherence to guidelines for diabetes management
continues to be poor (Canadian Diabetes Association | Diabète Quèbec, 2011; Diabetes Canada,
2018b). While self-management plays a large role in the disease course, treatment
recommendations originate in the hands of the family physician (Diabetes Canada, 2018b).
Studies have shown that prescription rates for medications to control diabetes-associated
complications are below national guidelines, providing an opportunity for intervention (Braga et
al., 2010). While many strategies exist for changing physician behaviour, PEMs have seen the
most widespread use despite having inconclusive evidence for their effectiveness. The most
recent systematic review revealed that PEMs are ineffective at changing provider behaviour
(Grudniewicz et al., 2015a). However, rather than dissuading researchers from using PEMs, the
authors provide direction for future research on PEMs (Grudniewicz et al., 2015a). They
recommend that researchers provide a clear description of the intervention and how it was
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developed to determine whether the PEM was optimized, as well as powering the study to be
able to detect the intended effects (Grudniewicz et al., 2015a).

The OPEM programme offers a means for evaluating the effectiveness of PEMs through large
scale, pragmatic RCTs. The first two trials in the OPEM series have been analyzed and published
(Zwarenstein et al., 2014; Zwarenstein et al., 2016); however, the trial investigating the
effectiveness of PEMs in terms of improving adherence to guideline recommendations for
managing the cardiovascular risks associated with diabetes has not yet been analyzed due to a
shortage of resources. At the time of the trial, antihypertensives and cholesterol-lowering agents
were proven to effectively manage cardiovascular risks, and a substantial number of patients
required more than one antihypertensive to reach target BP levels (UK Prospective Diabetes
Study Group, 1998b; Heart Protection Study Collaborative Group, 2003; Diabetes Canada,
2018b). Accordingly, the trial aimed to increase prescribing rates of antihypertensives (including,
specifically, angiotensin converting enzyme (ACE) inhibitors and “other” antihypertensives,
such as angiotensin II receptor blockers (ARBs), beta-blockers, calcium channel blockers, and
diuretics) and cholesterol-lowering agents (Zwarenstein et al., 2007). Research has since
revealed that antihyperglycemic agents can also be effective at reducing the cardiovascular risks
associated with diabetes (Diabetes Canada, 2018b). Nevertheless, BP and cholesterol-lowering
agents remain important therapies to mitigate the risk factors associated with CVD, a disease that
continues to be prevalent among diabetes patients (Diabetes Canada, 2018b). Accordingly,
analyzing the results from this trial will still provide valuable information today. By including a
large proportion of Ontario FP/GPs in the study population, the study was adequately powered to
detect the intended effect. Furthermore, detailed information about the intervention was
provided, including an image of the original PEMs, allowing researchers to determine whether
the PEM was optimized. Adhering to the recommendations outlined in the latest systematic
review, this trial has the capacity to significantly contribute to the debate surrounding the
effectiveness of PEMs.
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1.3 Objectives and Hypotheses
1. What is the effectiveness of a two-page (insert) PEM at intensifying FP/GP prescribing
rates for diabetes treatment?

Hypothesis: It is expected that prescribing practices among physicians who receive the
two-page insert will be superior to those who do not receive the insert.

2. What is the effectiveness of a short, directive (outsert) PEM at intensifying FP/GP
prescribing rates for diabetes treatment?

Hypothesis: It is expected that prescribing practices among physicians who receive the
short, directive outsert will be superior to those who do not receive the outsert.

3. Does the effect of the two-page (insert) PEM differ based on the presence of the short,
directive (outsert) PEM (test of interaction)?

Hypothesis: It is expected that the effect of the insert is independent of the effect of the
outsert.

4. A subgroup analysis will be carried out to determine whether newly diagnosed diabetes
patients are more likely to receive treatment intensification compared to those who have
had diabetes for many years.

Hypothesis: It is expected that patients who have been diagnosed with diabetes for
extended periods of time may be on a stable treatment regimen and are thus less likely to
alter this regimen in response to PEMs.
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1.4 Role of the student
I had no involvement in the design or the implementation of the OPEM programme. Trial data
were obtained, cleaned, and converted to level 4 student access by an analyst at ICES Western.
Since the trial was conducted a number of years ago and the protocol lacked specific information
on the trial, I worked with a team at ICES Western to develop a detailed dataset creation plan
from the raw data. Although the basic analysis plan is traditional for an RCT and follows the
original broad OPEM protocol, the specifics of these analyses and a number of additional
analyses were planned by myself, together with my supervisors. I conducted all analyses and
interpreted the results with the help of my thesis committee. I was responsible for writing all
chapters of the final thesis.

1.5 Format
This thesis consists of five chapters, beginning with the introduction in chapter 1. Chapter 2
presents a review of the literature, including the current understanding of the effectiveness of
printed educational materials and the present state of diabetes in Ontario. The following chapter,
chapter 3, provides a description of the research methodology and the data sources. The study
results, including multiple logistic regression models, are outlined in chapter 4. The final chapter,
chapter 5, draws conclusions based on the results, lists the strengths and limitations of this
research, integrates it with recent literature, and provides direction for future research.
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Chapter 2
2

Literature Review

This chapter is composed of five sections and provides an overview of the current literature,
beginning with the evidence-to-practice gap and the barriers to implementing evidence-based
practices in primary care in section 2.1. The following section, 2.2, introduces knowledge
translation and the common strategies used to mitigate the evidence-to-practice gap. The
predictors of clinical behaviour are outlined in section 2.3. Printed educational materials, a
frequently used knowledge translation intervention, are discussed in section 2.4 in terms of both
their ability to influence practice and their cost-effectiveness. A general overview of diabetes and
diabetes epidemiology is then provided in section 2.5, followed by a section on the complications
associated with diabetes and treatment strategies. This section will also discuss the barriers to
optimal management.

2.1 The evidence-to-practice gap
Evidence based medicine (EBM) is defined as the “conscientious, explicit, and judicious use of
current best evidence in making decisions about the care of individual patients” (Sackett et al.,
1996). Integrating the findings from the nearly 2.5 million scientific articles published each year
into routine practice does not itself generate EBM; rather, health care providers must combine
the relevant scientific evidence with their clinical expertise regarding their patients symptom
profile, their history, and their values to deliver the highest quality of care (Sackett et al., 1996;
Ware & Mabe, 2015). As a result, medical decisions should not follow a “cookbook approach”,
but instead require that health care providers exercise their best judgment to reconcile the
available evidence and the individual patient’s unique needs on all decisions made for each
individual patient (Sacket et al., 1996). This requirement for both evidence-based and
individualized care poses a challenge to health care providers, who already experience
substantial demands on their time (Dugdale et al., 1999). Consequently, the evidence-to-practice
gap emerges.
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As discussed in section 1.1, the evidence-to-practice gap reflects the disconnect between what
researchers know about what works, and what clinicians actually decide and recommend in their
daily clinical decision making. These gaps emerge as a result of both clinicians not knowing
what the guidelines are due to a lack of knowledge, and due to clinicians being aware of the
guidelines, but choosing not to follow them. There are many examples of evidence-to-practice
gaps in the medical literature (Grol & Grimshaw, 2003; Morales et al., 2013; Tan et al., 2008).
For example, despite decades of well-established evidence for the benefits of thorough
handwashing, compliance to handwashing procedures among health care providers continues to
be poor (Grol & Grimshaw, 2003). For a second example, in family medicine practice, a
significant proportion of Bell’s Palsy patients are not receiving treatment with corticosteroids in
spite of high-quality evidence demonstrating the effectiveness of this drug class (Morales et al.,
2013). Moreover, extensive evidence exists to contest the use of antibiotics for the treatment of
most acute respiratory tract infections; nonetheless, antibiotics continue to be widely prescribed
(Tan et al., 2008). The consequences associated with these gaps are marked. Patients failing to
receive effective care, and, in some cases, receiving harmful treatments, health care providers
wasting their time and social resources applying outdated and ineffective guidelines, and medical
advances with proven efficacy being ignored, among many more.

Studies addressing the evidence-to-practice gap have only recently become prominent in the
clinical research community. In the past, researchers have mainly focused on conducting studies
in specific patient groups to yield novel findings that merit publication in prestigious journals
with the assumption that widespread uptake of effective treatments would follow naturally
(Bauer et al., 2015). RCT researchers have typically not been concerned with the application of
their findings to routine practice and to diverse patient groups (Bauer et al., 2015). However,
with increasing concerns about the applicability of such trials, and decreasing funding for
research globally, funding agencies have had to prioritize the type of studies they can support
and have thus gained a deeper appreciation for studies with potential public health impact (Bauer
et al., 2015). As a result, more applicable studies, and more studies focused on KT and
implementation research, have emerged.
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2.1.1 Evidence-to-practice gaps in primary care
Evidence-to-practice gaps are especially common in primary care practices (Lau et al., 2014).
According to Lau and colleagues, “primary care has its own distinctive research and
implementation culture”, which has been described as contributing to the evidence-to-practice
gap (Lau et al., 2014). The integration of new interventions in primary care is challenged by the
diversity of the practices. Each practice is unique in terms of its team composition, culture, and
working practices (Lau et al., 2014). While the complexity of teams is beneficial in terms of
providing a more comprehensive approach to care, it can heighten the evidence-to-practice gap.
Furthermore, it has been argued that achieving change in primary care practice often requires
complex interventions that necessitate change at multiple levels, making the implementation
process more challenging (Lau et al., 2014).

PCPs face many barriers to implementing EBPs and their resistance to integrating new
knowledge has been extensively researched. PCPs have been known to consider general practice
and research as two separate entities, reasoning that research is so far from patient centered care
that it cannot be effectively incorporated into routine practice (Salmon et al., 2007). Reasons for
disregarding EBPs are multifaceted and depend on the type of behaviour change that the
intervention aims to target (Carleson et al., 2007). Interventions that attempt to eliminate a
physician behavior (proscriptive interventions) are more challenging to implement than are
interventions encouraging a new behaviour (prescriptive interventions), as the physician risks
compromising a positive relationship they’ve maintained with their patients by eliminating
common practices (Carleson et al., 2007). The integration of EBPs, especially those that require
services to be rationed, threaten to compromise this relationship and therefore become less of a
priority for PCPs (Carleson et al., 2007). Among the reasons for PCP resistance to EBPs includes
the broad nature of conditions they treat (Hannes et al., 2005). PCPs are confronted with a wide
range of patients each day who often present with vague symptoms and pose general questions
relating to their health (Hannes et al., 2005). As a result, PCPs must possess a broad
understanding of all symptoms and conditions. For this reason, they express that staying
informed on current knowledge in all areas of general medicine is challenging (Hannes et al.,
2005). Similarly, what PCPs experience in primary care is different from that of clinicians
providing secondary care (Freeman & Sweeney, 2001). In a qualitative study, PCPs reported that
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specialists treated “diseases rather than patients”, making it easier to stay up to date on new
advancements compared to their obligation to treat the patient as a whole, taking into account
family and social context rather than simply treating a series of diseases (Freeman & Sweeney,
2001). PCPs also attribute their resistance to EBPs to the complexity of consultations in primary
care (Carleson et al., 2007). The relative simplicity of guidelines often overlooks the struggles of
treating complex individual circumstances, including patient preference, co-morbidities, and
adverse events (Carleson et al., 2007). Lastly, PCPs’ personal and professional experiences,
including both successes and failures, dictate how they treat their patients (Freeman & Sweeney,
2001; Carleson et al., 2007).

2.2 Translating research into practice
Despite only recently gaining a formal definition, the concept of KT dates back to the early
1900s (Tarde, 1903). Sociologist Gabriel Tarde recognized that certain innovations were not
being adopted in society and offered insight into factors that may affect implementation
(Grimshaw et al., 2012). Several years later, in 1983, Everett Rogers developed the diffusion of
innovation theory in attempts to better understand how new ideas are spread (Rogers, 1983). His
theory suggests that the following four elements determine how effectively a new idea is spread:
the innovation, communication, time, and social system (Rogers, 1983). However, a commitment
to studying KT strategies to address the evidence-to-practice gap has only recently become
widespread. In 2000, the Canadian Institute for Health Research released the first official
definition of KT as the “exchange, synthesis and ethically-sound application of knowledge—
within a complex system of interactions among researchers and users—to accelerate the capture
of the benefits of research for Canadians through improved health, more effective services and
products, and a strengthened health care system” (Canadian Institute for Health Research, 2004).
Since then, many modifications to the definition have been released; however, the fundamental
concept remains the same: KT strategies aim to facilitate the exchange of information between
researchers and users. A main point highlighted by the Canadian Institute for Health Research is
the need for continuous dialogue and interaction between researchers and users throughout the
entirety of the process (Sudsawad, 2007). Researchers have compiled a list of desirable features
of KT interventions, including, but not limited to, a clear statement of the tool’s objectives,
providing instructions to users, including users in the development process, and collecting user
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feedback (Moore et al., 2017). While Canada has adopted the term “knowledge translation”,
many terms exist that are used interchangeably globally (Graham et al., 2006). A study revealed
that 29 different terms exist to describe the concept of translating research into practice,
including knowledge exchange, research utilization, implementation and dissemination (Graham
et al., 2006).

To promote the successful uptake of KT interventions, knowledge producers are encouraged to
answer five questions before implementing their intervention (see table 1.1) (Lavis et al., 2003).
These questions are intended to force researchers to consider key design elements to ensure that
the effect of their intervention is optimized.

Table 1.1: Questions to consider during the development process of a new intervention
Question
What should be transferred to decision makers?
To whom should research knowledge be
transferred?
By whom should research knowledge be
transferred?

How should research knowledge be transferred?
With what effect should research knowledge be
transferred?

Considerations
Transfer “actionable messages” from
multiple studies, rather than a single study
Primary target audience depends on the
nature of the information to be transferred
(see Appendix 1)
Choose credible messengers
Endorsement by professional
organizations and respected colleagues
influences knowledge uptake
Weigh the facilitators and barriers to
specific intervention strategies
Select performance indicators to measure
whether knowledge is used
Measure how knowledge is used (i.e. in
instrumental, symbolic, conceptual ways)

Data sources: Lavis et al (2003); Grimshaw et al (2012).

2.2.1 Knowledge translation interventions in the health care field
KT interventions are frequently utilized in the health care field and exist in many different forms.
Interventions are classified into the following 3 categories based on the nature of their objective:
resource planning, implementation, and evaluation (Moore et al., 2017). Interventions focused on
resource planning include strategies to assess costs, equipment and technology requirements, and
staff education and training, among many more (Gagliardi et al., 2014). Implementation tools
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focus on the assessment of barriers and enablers to intervention adoption and point-of-care tools
that determine how the clinician practices (Gagliardi et al., 2014). Evaluation tools include
quality indicators, performance measures, and relevant benchmarks (Gagliardi et al., 2014).

Since interventions characterized by implementation tools are frequently used in the health care
field, and are the main topic of this thesis, they will be discussed in greater detail (Moore et al.,
2017). Educational materials and decision aids are among the most commonly used intervention
tools due to their adaptability to a wide variety of scenarios (Moore et al., 2017). Educational
materials exist in many forms, such as infographics, clinical practice guidelines and frequently
asked questions (Moore et al., 2017). While traditionally delivered in print, the increased use of
electronic systems in the medical field has allowed for educational materials to also be delivered
electronically (Moore et al., 2017).

Decision aids share many characteristics with educational materials; however, their explicitness
in terms of the decision in question sets them apart (Moore et al., 2017). Common formats of
decision aids include decision trees, infographics, and algorithms (Moore et al., 2017). Despite
being a valid tool to inform all of clinicians, patients, and caregivers, decision aids are most
frequently used as a tool to inform patients (Moore et al., 2017).

Among the other KT interventions that have seen widespread use is audit and feedback. Audit
and feedback systems are used to improve the quality of care delivered by clinicians by
providing them with feedback on their routine clinical performance (Flottorp et al., 2010). Audit
and feedback interventions are often paired with other tools, such as educational materials, to
promote intervention uptake by highlighting the most effective approaches to care (Flottorp et
al., 2010). By comparing clinicians’ current practices with best practices, the evidence-topractice gap is highlighted and may prompt change.

Another KT strategy commonly used is reminders. Reminders may be delivered on paper or
electronically, and are used to prompt desired behaviours or actions (Grimshaw et al., 2012).
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Local opinion leaders have also been used in attempts to promote intervention uptake in the
health care field. Researchers hypothesize that individuals who are credible, trustworthy, and
likeable have a greater ability to drive behaviour change (Flodgren et al., 2011). As a result, local
opinion leaders have often been tasked with delivering educational messages to clinicians in
attempts to emphasize the evidence-to-practice gap and to prompt behaviour change (Flodgren et
al., 2011).

Similarly, educational outreach visits have been postulated to evoke change in health care
settings. Outreach visits are mainly used to inform clinicians on a one-on-one basis on topics
relevant to their specific practice, delivered by knowledgeable experts in the field (Centre for
Effective Practice, 2018).

Furthermore, educational meetings have been suggested as a tool for KT. The nature of
educational meetings can be didactic, addressing knowledge barriers, or interactive, addressing
attitudes, skills and knowledge (Grimshaw et al., 2012).

Patient-mediated interventions have also been used as a KT strategy to enact change among
clinicians. These interventions attempt to change clinician performance through patient
education and appear in many forms, such as patient decision aids, the inclusion of patients on
committees and boards, and patient-led training of health care providers (Fønhus et al., 2018).

Lastly, local consensus processes enable shared decision-making to assist groups of people in
attaining agreement on issues in the health care field (Nasser et al., 2017). It is hypothesized that
including people in the decision-making process evokes a sense of ownership and commitment
to adhering to the proposed change; therefore, local consensus processes are thought to be a
means of bridging the evidence-to-practice gap (Nasser et al., 2017).

2.2.2 The effectiveness of knowledge translation interventions
Despite the multitude of tools available for KT in the health care field, evidence-to-practice gaps
remain widespread, prompting researchers to investigate the effectiveness of the available
strategies. The development of the diverse array of KT strategies arose partly due to the
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discovery that traditional continuing medical education activities, such as lectures and case
methods, were generally ineffective at stimulating change in clinical decision making and
practice among clinicians (Davis et al., 1999; Sandelowsky et al. 2018).

In early systematic reviews on KT interventions, researchers discovered that passive
interventions, such as educational materials and didactic lectures, are less effective at initiating
change compared to active interventions, such as outreach visits and interactive educational
meetings (Bero et al., 1998). However, passive dissemination strategies continue to be used
extensively today and their effects appear to be mixed (Grimshaw et al., 2012; LaRocca et al.,
2012). Educational materials and reminders, both passive interventions, were found to improve
care by 4.3% and 4.2%, respectively (Grimshaw et al., 2012). Educational outreach and
educational meetings, two active interventions, resulted in absolute improvements in care of
4.8% and 6%, respectively (Grimshaw et al., 2012). Though the active strategies did yield
greater improvements than the passive strategies, the magnitude of the difference is not large
enough to discount passive interventions as effective KT tools. Furthermore, certain single
component interventions have performed as well as their multi-component counterparts,
indicating that simple interventions have the potential to induce change (Grol & Grimshaw,
2003; LaRocca et al., 2012). Researchers have suggested that overly complex interventions may
even be less likely to be integrated into practice, as the excess information may dilute the key
messages (Dobbins et al., 2009).

The inconsistency in findings has led to the continued use of KT strategies despite uncertainties
about their true effectiveness. Most well-designed interventions have some effect, but there is not
one “gold-standard” intervention that successfully promotes change in all settings (Grol &
Grimshaw, 2003).

2.3 Predictors of clinical behaviour
To understand the inconsistencies in the provision of care, researchers have attempted to quantify
the factors that influence physician performance. These characteristics can be grouped into three
categories: physician factors, organizational factors, and systemic factors (Wenghofer et al.,
2009). Among the frequently studied physician factors include physician age and sex. Studies
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have shown that increasing age is correlated with poorer adherence to therapeutic standards,
increased rates of inappropriate prescribing, and increased patient mortality (Anderson et al.,
1997; Tsugawa et al., 2017). Similarly, as the number of years in practice increase, physician
performance tends to decline (Choudhry et al., 2005; Cadieux et al., 2007). As physicians gain
years of experience, they begin to accumulate a personal drug formulary from which they
routinely prescribe, making it challenging to integrate new therapeutics when they are
recommended in clinical guidelines (Carthy et al., 2000). The differences between males and
females are less pronounced. Nevertheless, it has been reported that higher patient mortality rates
are linked to male physicians (Davidson et al., 1995). Furthermore, another study revealed that
female physicians perform better in the following areas: acute care, health maintenance, and
managing patient records (Wenghofer et al., 2009). The impact of physician certification has also
been studied. Physicians who are certified by the College of Family Physicians of Canada have
been shown to deliver enhanced care in terms of health maintenance and managing patient
records (Wenghofer et al., 2009). Physicians with a speciality certification were also found to
provide enhanced patient care, as they are more likely to prescribe the most appropriate and
effective drugs (Anderson et al., 1997). Lastly, the physician’s place of training has been
proposed to influence their performance (Cadieux et al., 2007; Wenghofer et al., 2009). It was
determined that internationally trained physicians are more likely to prescribe inappropriate
antibiotics compared to their Canadian trained counterparts (Cadieux et al., 2007). However,
Wenghofer et al. (2009) showed that there is no significant difference in performance between
physicians trained in North America and those trained elsewhere. The following physician
characteristics have been investigated but failed to demonstrate a significant effect on
performance: years practising with current patient population, and whether the physician has
undergone peer assessment by the College of Physicians and Surgeons of Ontario (Wenghofer et
al., 2009).

Organizational factors comprise the characteristics of the physicians working practice
(Wenghofer et al., 2009). The number of patients seen per week has been shown to significantly
influence physician performance (Wenghofer et al., 2009). Those who see fewer patients per
week perform better in the following key dimensions: acute care, chronic care, continuity of
care, health maintenance, and record management (Wenghofer et al., 2009). Furthermore, larger
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patient volumes have been associated with increased rates of inappropriate antibiotic prescribing
and higher patient mortality (Davidson et al., 1995; Cadieux et al., 2007). The effect of the
number of yearly billings on physician performance has also been a variable of interest. Patients
of physicians who bill larger amounts per year experience higher mortality rates than those who
bill smaller amounts (Davidson et al., 1995). Lastly, physicians who hold active hospital
privileges have been shown to outperform those who work solely as a GP (Wenghofer et al.,
2009). Factors of interest that have not been proven to be significant include the number of staff
per practice (including both clinical and administrative staff), number of hours worked per week,
and whether the physician works in solo or group practice (Wenghofer et al., 2009).

Systemic factors are those associated with the broader context in which the physician works
(Wenghofer et al., 2009). Practice location significantly impacts performance due to resource
availability. In a study among Ontario physicians, those working in Southern communities
significantly outperformed those practicing in Northern areas in acute care, health maintenance,
and records management (Wenghofer et al., 2009). Moreover, it has been shown that Canadian
physicians working in rural areas are less likely to comply with diabetes guideline
recommendations than are physicians working in urban areas (Worrall et al., 1997). A factor that
is often related to practice location is the physician-to-population ratio (Wenghofer et al., 2009).
Physicians with higher physician-to-population ratios perform better in terms of acute care,
chronic care, and continuity of care compared to those with smaller ratios (Wenghofer et al.,
2009). Lastly, practices with a greater abundance of resources have enhanced performance
(Wenghofer et al., 2009). The availability to order basic diagnostic tests improves chronic care,
continuity of care, and health maintenance (Wenghofer et al., 2009). The effect of 911 service
accessibility and time to emergency medical services have both been studied but have failed to
show significant effects on physician performance (Wenghofer et al., 2009).

While the aforementioned studies have provided insight into the factors associated with
physician performance, they are equipped with a limitation that cannot be overcome. Since
neither patient symptoms, nor their disease course, are taken into consideration in these studies,
the authors are unable to conclusively confirm that variations in performance are solely due to
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physician characteristics, rather than the nature of their patient population. Nonetheless, the
characteristics that have been proven to influence performance will be studied in our population.

2.4 Defining printed educational materials
According to the Cochrane Effective Practice and Organisation of Care Review Group (2019),
PEMs are defined as the “distribution of published or printed recommendations for clinical care,
including clinical practice guidelines, audio-visual materials and electronic publications. The
materials may have been delivered personally or through mass mailings”. PEMs are a common
form of passive dissemination strategy that aim to mitigate the evidence-to-practice gaps
prevalent in the health care field to enhance patient care (Farmer et al., 2003). While PEMs can
be developed to target all members of the health care system, from patients to health care
organizations, they have been frequently used to address knowledge and skill gaps among health
care providers (Giguère et al., 2012).

The sole criteria required to be classified as a PEM is to provide a printed recommendation for
clinical care; thus, the characteristics of PEMs vary extensively. PEMs can differ based on
format, content, information source, and mode and timing of delivery, all of which contribute to
the effectiveness of the PEM (Farmer et al., 2003). The format of PEMs includes the appearance
and the length of the recommendation (Farmer et al., 2003). PEMs may be colorful or black and
white, written in traditional or creative fonts, and printed on glossy or matte paper (Farmer et al.,
2003). The length of PEMs is often determined by the context in which the recommendation is
delivered, and can range from brief messages to multi-page journal articles (Farmer et al., 2003).
For example, multi-page PEMs may be embedded in journals sent to providers, whereas short
updates may be delivered on their own. The minimal criteria for PEMs also allows them to vary
greatly in terms of content. The topic of PEMs may cover any clinical area, particularly focusing
on areas in which care is below standard. Furthermore, PEMs may be tailored to specific
audiences, such as PCPs, or may be generic, targeting diverse groups of individuals (Farmer et
al., 2003). Lastly, the source of information used to develop recommendations determines the
credibility of a PEM. PEMs may be developed by a variety of sources, including official
organizations, such as the College of Physicians and Surgeons of Ontario, corporate sources, and
governmental agencies (Farmer et al., 2003).
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2.4.1 Do printed educational materials change provider behavior?
PEMs have a long history of use to address evidence-to-practice gaps (Farmer et al., 2008).
However, despite their prominence in the health research community, the effectiveness of PEMs
is still poorly understood. Bero et al. (1998) were the first to question effectiveness of PEMs.
The authors provided strong evidence suggesting that the effect of educational materials on
changing provider behaviour is little to none, and instead recommended that more intensive
interventions should be utilized to alter practice (Bero et al., 1998). However, this revelation
failed to dissuade trialists from delivering PEMs to health care providers to promote the uptake
of research findings. A 2003 review similarly found that educational materials are generally
ineffective at changing provider behaviour (Grol & Grimshaw, 2003). However, the authors note
that inadequately powered and poorly analyzed studies dominate the literature (Grol &
Grimshaw, 2003); therefore, to ascertain the true effectiveness of PEMs, studies of higher quality
are required. The succeeding systematic review was published in 2004 and suggested that PEMs
modestly improve guideline implementation (Grimshaw et al., 2004). The authors reported that
PEMs resulted in absolute improvements in performance ranging from 3.6% to 17%, with a
median absolute improvement of 8.1% (Grimshaw et al., 2004). Despite also making reference
the poor quality of studies, Grimshaw et al. (2004) concluded that PEMs should not be
disregarded as a strategy to change provider behaviour. They alluded to the fact that in many
situations, resources for behaviour change interventions are scarce; therefore, policy makers
should carefully estimate the benefits and costs of the desired intervention (Grimshaw et al.,
2004). These promising results were the catalyst for the development of the OPEM programme
to further investigate the effect of PEMs. The OPEM programme is discussed in greater detail in
section 3.3.

Several reviews have been published since the OPEM programme was conducted. In 2008, a
review by Farmer et al. supported the claim of effectiveness made by Grimshaw et al. (2004).
While PEMs were generally shown to be ineffective when compared to other intervention types,
when compared to no intervention, they led to statistically significant improvements in care
(Farmer et al., 2008). The authors concluded that, while small, the benefits of PEMs are apparent
and merit further study (Farmer et al., 2008). Two additional reviews were conducted in 2012.
Ho & Venci (2012) investigated the effect of mailed letters on the prescribing behaviours of
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physicians and found that mailed letter interventions, when well-orchestrated, have the potential
to influence physician behaviour. Of the RCTs included in the review, 53.3% found that PEMs
successfully impacted prescribing habits (Ho & Venci, 2012). Observational studies yielded
larger effects, with 85.7% finding a positive association between mailed letters and physician
prescribing patterns (Ho & Venci, 2012). However, the authors again concluded that, while it
appears that prescribers are open to change in response to a mailed letter, definitive conclusions
could not be drawn due to the heterogeneity of the articles in the literature (Ho & Venci, 2012).
The second review conducted in 2012 revealed similar results (Giguère et al., 2012). While it
was determined that PEMs have a small positive effect on provider behaviour when compared to
no intervention, the authors concluded that the poor quality of the current evidence takes away
from the strength of their conclusions (Giguère et al., 2012). The most recent review on the
effectiveness of PEMs was undertaken in 2015 (Grudniewicz et al., 2015 a). The authors
acknowledged that the nature of the health care setting likely impacts the effectiveness of PEMs
and thus focused their review on primary care practices specifically (Grudniewicz et al., 2015a).
This review concluded that, at present, PEMs do not improve outcomes, neither at the PCP level,
nor at the patient level (Grudniewicz et al., 2015 a). The authors suggest that the positive results
identified in previous reviews may be due to the inclusion of specialist physicians, as they are
likely to respond differently to PEMs than are PCPs (Grudniewicz et al., 2015a). Instead of
dissuading researchers from studying the effects of PEMs, the authors provide direction for
future research that is required before ruling out this widely used dissemination strategy
(Grudniewicz et al., 2015a). Some of the characteristics of the desired future studies include the
improved design of PEMs, more detailed descriptions of the intervention, and sufficiently
powered analyses (Grudniewicz et al., 2015a).
Today, the effect of PEMs continues to be researched. A study published in 2019 investigated
the effect of PEMs on guideline adherence among PCPs and found that PEMs had a beneficial
effect on providers compliance to clinical recommendations (Boltin et al., 2019). The odds of
PCP behaviour change were 64% higher (p=0.04) among those who were exposed to PEMs
compared to those who received no intervention (Boltin et al., 2019).
The effectiveness of PEMs warrants further investigation. Throughout the years, researchers
have drawn repeatedly changing conclusions surrounding their effectiveness, and, to this day,
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their ability to influence practice remains unknown. As a result, more trials investigating PEMs
are needed. The present thesis analyses the results from an unreported trial from the OPEM
programme. The conclusions drawn from the most recent systematic review were influenced by
the first OPEM trial that was published, as it was a large-scale, pragmatic trial with a low risk of
bias (Grudniewicz et al., 2015 a). Accordingly, the results from the OPEM trial analyzed in this
thesis are likely to be influential.

2.4.2 Cost-effectiveness of printed educational materials
The most commonly cited reason for using PEMs as a KT strategy despite understanding that
their effectiveness has been repeatedly doubted is the low costs associated with implementation.
In reviews that found PEMs to be relatively ineffective at changing provider behaviour, the
authors often concluded that PEMs should not be disregarded due to their low cost and the ease
with which wide coverage could be achieved (Grimshaw et al., 2004; Farmer et al., 2008).
However, concrete evidence surrounding the cost effectiveness of PEMs is lacking.

A recent European study attempted to establish the implementation strategies that are the most
effective given their costs (Mewes et al., 2017). It was determined that the costs associated with
PEMs were substantially lower than other intervention strategies (Mewes et al., 2017). The total
cost to mail a PEM, on three occasions, to a single provider, was €18 (Mewes et al., 2017).
Compared to reminder systems and audit and feedback, which incurred costs of €77 and €1,075
per provider, respectively, PEMs are a relatively inexpensive intervention strategy (Mewes et al.,
2017). A study by Padwal et al. (2017) confirmed this claim. In their study, three interventions
that aimed to improve self-management strategies for bariatric care were compared in terms of
effectiveness and cost (Padwal et al., 2017). The cost of mailing a single PEM to each individual
was $1.33 (Padwal et al., 2017). In comparison, an in-person educational strategy and a webbased educational strategy cost $273.40 and $5.54, respectively (Padwal et al., 2017). Given that
there was no significant difference between patient outcomes in the three intervention groups, the
authors concluded that more intensive and costly strategies are not necessarily superior to
cheaper, less effective options (Padwal et al., 2017).
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The cost-effectiveness of PEMs was quantified in a 2004 study by Paul et al. PEMs were
developed to provide women with information on a Pap Test Reminder Service (Paul et al.,
2004). The authors compared the following three PEMs in terms of their cost to implement: a
pamphlet incorporating literature characteristics only (‘C’), a pamphlet incorporating both
literature characteristics and behavioural strategies (‘C + B’), and a pamphlet incorporating all of
literature characteristics, behavioural strategies, and marketing strategies (‘C + B + M’) (Paul et
al., 2004). Total costs were calculated by summing staffing costs (i.e. draft development and
graphic designers), printing costs, and consumables costs (i.e. postage and supply costs) (Paul et
al., 2004). The cost-effectiveness of each PEM was ascertained by dividing the costs by the
number of women who joined the program in response to the PEM (Paul et al., 2004). The cost
per women enrolled in the program for ‘C’, ‘C + B’, and ‘C + B + M’ was (AUD) $34.55,
$21.33, and $22.78, respectively (Paul et al., 2004). Accordingly, the authors concluded that the
pamphlet that incorporated both literature characteristics and behavioural strategies was the most
cost-effective (Paul et al., 2004). More recently, Hallsworth et al. (2016) completed a similar
cost effectiveness analysis on printed materials. Their study aimed to reduce inappropriate
antibiotic prescribing among GPs by sending letters outlining their prescribing patterns relative
to their peers (Hallsworth et al., 2016). They found that the cost per prescription prevented was
£0.06, and, given the interventions success, concluded that these letters substantially reduce
inappropriate prescribing at low costs (Hallsworth et al., 2016).

While the literature on the cost-effectiveness of PEMs is sparse, the available studies have
revealed that the implementation of PEMs requires dramatically lower costs than other
intervention strategies. Until we have strong evidence to suggest that PEMs are not effective, and
given their low cost and apparent absence of harm, there is value in continuing to evaluate the
cost-effectiveness of this KT strategy.

2.5 Diabetes mellitus
Diabetes mellitus, referred to as diabetes hereafter, is defined as a “heterogenous metabolic
disorder characterized by the presence of hyperglycemia due to impairment of insulin secretion,
defective insulin action, or both” (Diabetes Canada, 2018b). Insulin is a hormone used to regulate
blood sugar levels. In diseased states, the body is unable to properly use insulin and thus
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develops abnormal blood sugar levels, known as hyperglycemia. The mechanism by which
hyperglycemia develops determines the nature of the diabetes diagnosis. Diabetes is classified
into 4 categories: T1DM, T2DM, gestational diabetes, and other specific types. The majority of
individuals with diabetes are diagnosed with either T1DM or T2DM; therefore, these disorders
will be discussed in further detail in sections 2.5.1 and 2.5.2, respectively. Diagnosing diabetes is
done through a variety of blood samples and laboratory tests, including a fasting plasma glucose
test, a two-hour plasma glucose test, and a hemoglobin A1C test (Diabetes Canada, 2018 b).

The symptom profile of individuals with diabetes differs based on the specific type of diabetes.
However, common symptoms experienced by individuals with diabetes include increased thirst
(polydipsia), frequent urination (polyuria), fatigue, weight change, and recurring infections
(Diabetes Canada, 2019f). These symptoms, if improperly managed or left untreated, can give
rise to numerous serious, and sometimes fatal, complications. These will be discussed in section
2.5.4.

2.5.1 Type 1 diabetes mellitus
T1DM, also known as insulin-dependent diabetes, is an autoimmune disease characterized by the
inability to produce insulin (Diabetes Canada, 2018b). Though the underlying mechanism of
T1DM remains unknown, researchers suspect that it results from the destruction of pancreatic
beta cells, the cells responsible for producing insulin (Diabetes Canada, 2018b). Without insulin,
sugars from ingested foods are unable to be used for energy and instead accumulate in the blood.
Consequently, those with T1DM often require daily insulin injections to fill this void to maintain
healthy blood sugar levels (Diabetes Canada, 2019f). Inadequate insulin supplementation can
lead to diabetic ketoacidosis, a condition that is particularly concerning among individuals with
T1DM (Diabetes Canada, 2018b). Without insulin, the body is unable to use glucose as fuel and
thus compromises by burning fats (American Diabetes Association, 2019). The breakdown of fat
produces a chemical called ketones, which increase the acidity of the blood and leads to several
dangerous symptoms, including diabetic coma and death (American Diabetes Association,
2019).
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While the majority (80-90%) of diabetes cases that develop during childhood or adolescence are
T1DM, the onset of this disease can also occur in adulthood, complicating the ability to
accurately diagnose this disease (Kharroubi & Darwish, 2015). Numerous factors have been
hypothesized to give rise to beta cell destruction, such as genetic predisposition, exposure to
viruses, and exposure to environmental factors (Kharroubi & Darwish, 2015). That being said,
T1DM is not preventable. The onset of T1DM is often sudden, causing immediate symptoms
such as polydipsia, polyuria, extreme hunger (polyphagia), sudden weight loss, and blurred
vision (Kharroubi & Darwish, 2015). While unfortunate and troublesome, the sudden onset of
symptoms can allow for a quicker diagnosis and improved prognosis. Aside from the general
complications associated with diabetes (see section 2.5.4), individuals with T1DM are at a
greater risk of developing other autoimmune disorders, such as Addison’s disease, celiac disease,
and Grave’s disease (Kharroubi & Darwish, 2015).

2.5.2 Type 2 diabetes mellitus
T2DM is characterized by insulin resistance. While the beta cells of the pancreas are able to
produce insulin, in contrast with T1DM, often not enough insulin is produced, or the body is
unable to make proper use of it (Diabetes Canada, 2018b). As a result, blood sugar levels begin to
rise. The insulin secretion, albeit small, usually allows individuals with T2DM to cope without
the need for daily insulin supplementation (Kharroubi & Darawish, 2015). However, over time,
the increased demand for insulin production can damage beta cells, resulting in insulin depletion
that may eventually require daily insulin supplementation (Kharroubi & Darawish, 2015).

Unlike T1DM, T2DM can, in some cases, be prevented. Researchers believe that the worldwide
obesity epidemic has contributed substantially to the rise in T2DM diagnoses (Kharroubi &
Darawish, 2015). Accordingly, by maintaining a heathy body weight, engaging in regular
physical activity, and eating a well-balanced, nutritious diet, individuals are able to reduce their
likelihood of developing obesity and subsequently diabetes. However, like T1DM, genetic
factors are also predicted to play a role in the development of T2DM (Wu et al., 2014). While the
role of many genes has been studied, the TCF7L2 gene has been identified as the largest
contributor to T2DM susceptibility (Gloyn et al., 2009). Moreover, individual characteristics
such as age, sex, and ethnicity have been shown to play a role in the development of T2DM
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(Khan et al., 2010). While the onset of symptoms in T1DM is sudden, individuals with T2DM
experience a more gradual development of symptoms. In fact, individuals can live with T2DM
for many years before presenting any symptoms. As a result, diagnosing T2DM is challenging,
and delayed diagnoses can lead to heightened long-term complications (Kharroubi & Darawish,
2015).

2.5.3 Diabetes epidemiology
According to the WHO (2016), “diabetes is one of the biggest global health crises of the 21st
century”. In 1980, the estimated worldwide prevalence of diabetes was 108 million, or 2,436
cases per 100,000 individuals (WHO, 2016; The World Bank, 2018). Over 30 years later, in
2014, the prevalence was reported to be 422 million, corresponding to 5,816 cases per 100,000
individuals (WHO, 2016; The World Bank, 2018). This alarming rise is largely fuelled by an
increase in the incidence of T2DM risk factors, mainly obesity and sedentary lifestyles (WHO,
2016). In 2016, approximately 1.6 million individuals died due to diabetes, making diabetes the
seventh leading cause of death worldwide (WHO, 2018). While the prevalence of diabetes has
seen the greatest increase in low- and middle-income countries, high-income countries, like
Canada, have not been spared (WHO, 2018).

Canadian statistics
Recent estimates suggest that one in three Canadians are either diagnosed with T1DM or T2DM,
or have elevated blood sugars indicative of a “pre-diabetes” state (Diabetes Canada, 2019e). This
corresponds to roughly 11 million Canadians directly affected by diabetes (Diabetes Canada,
2019d). Among Canadian individuals diagnosed with diabetes, 90-95% of them have T2DM
(Diabetes Canada, 2019e). While this disease can affect individuals of all ages, the majority of
cases are diagnosed among those 40 years or older (Doucet & Beatty, 2010). With an aging
population, experts predict that the prevalence of T2DM will continue to rise (Doucet & Beatty,
2010). That being said, some studies suggest that, while the incidence of diabetes rose between
1995 and 2005 in Canada, it has since begun to level off (Magliano et al., 2019). Along with the
increasing prevalence, the annual economic impact of diabetes has risen dramatically over the
years (Diabetes Canada, 2019d). From $6.3 billion in 2000, to $14 billion in 2008, to almost $30
billion in 2019, diabetes presents a large burden on health care systems (Doucet & Beatty, 2010;
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Diabetes Canada, 2019d). Estimates from the International Diabetes Federation (2019) suggest
that in 2019, 7.4% of the total health expenditure in Canada was attributable to diabetes.

Though diabetes can affect virtually anyone, certain individuals are at a greater risk of
developing this disease. In 2018, the prevalence of diabetes was greater in males than in females,
with 8.1% of males being affected and 6.2% of females (Statistics Canada, 2019). Furthermore,
among males, the highest prevalence of diabetes is reported in those aged 75 years and older
(Statistics Canada, 2018). In females, however, the prevalence of diabetes increases steadily until
the age of 74, after which the percentage of reported diabetes cases does not significantly
increase (Statistics Canada, 2018). Moreover, ethnicity has been reported to influence an
individual’s risk of developing T2DM due to a combination of biological and behavioural
differences (Government of Canada, 2011). Individuals of South Asian, Hispanic American,
Chinese, and African descent are more prone to developing T2DM than are individuals of
European descent (Government of Canada, 2011). While Caucasians reportedly engage in higher
levels of physical activity, they are also more likely to smoke (Government of Canada, 2011).

Ontario statistics
It is estimated that, among the 10,991,000 Canadians currently living with diabetes or prediabetes, 4,424,000 are Ontarians (Diabetes Canada, 2019d). Ontario’s high burden is, in part,
due to evolving immigration patterns, with Toronto being a common city for new residents
(Canadian Diabetes Association, 2011). The prevalence of diabetes in Ontario continues to rise,
placing a significant burden on the health care system.

A 2012 ICES study attempted to determine the spread of diabetes and its associated
complications across the 14 Local Health Integration Networks (LHINs) in Ontario (see
Appendix 2) (Booth et al., 2012). The highest prevalence of diabetes was reported in Central
West regions of Ontario, with a prevalence of 12.39% (Booth et al., 2012). The lowest
prevalence was seen in the following LHINs: South West, Waterloo Wellington, Toronto
Central, and North Simcoe Muskoka (Booth et al., 2012). In terms of hospital visits for hyper- or
hypoglycemia, the provincial rates varied two-fold, but averaged at 486 per 10,000 individuals
with diabetes (Booth et al., 2012). Individuals who experienced the greatest number of
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hospitalizations were concentrated in Southwestern, Southeastern, Central and Northern Ontario
regions (Booth et al., 2012). Furthermore, hospitalizations for cardiovascular events were
recorded, averaging at 888 per 10,000 Ontarians with diabetes (Booth et al., 2012). Northern
regions experienced hospitalizations as high as 1,376 per 10,000 individuals, whereas regions
such as Central and Mississauga Halton experienced as few at 705 hospitalizations (Booth et al.,
2012). The provincial average of lower extremity amputations was 74 per 10,000, but this
number varied by 3.5-fold across regions (Booth et al., 2012). While individuals in Northern
regions experienced rates as high as 148 per 10,000, those residing in Central areas experienced
as few as 42 lower limb amputations (Booth et al., 2012). Lastly, the rate of additional chronic
illnesses experienced by individuals with diabetes was measured (Booth et al., 2012). The
provincial average was 54.84%, and varied little between regions (Booth et al., 2012). Despite
this high prevalence of concomitant illnesses, only approximately one in three individuals paid a
visit to their health care provider for a psychotic or non-psychotic illness (Booth et al., 2012).

While the majority of health care is covered for Ontarians enrolled in the Ontario Health
Insurance Plan (OHIP), individuals are still required to pay out-of-pocket costs to effectively
manage their disease. These costs include, but are not limited to, medications, devices and
supplies (Canadian Diabetes Association | Diabète Quèbec, 2011). These out-of-pocket costs
vary significantly throughout Canada, with Ontario ranking well above the national average for
personal expenses for both T1DM and T2DM (Canadian Diabetes Association | Diabète Quèbec,
2011). Ontarian’s with T1DM are required to spend nearly $950 annually to manage their
diabetes, while those with T2DM are spending, on average, $2,173 per year (Canadian Diabetes
Association | Diabète Quèbec, 2011). Accordingly, in 2011, 57% of individuals living with
diabetes revealed that they do not fully comply with their treatment regimen as a result of the
associated costs (Canadian Diabetes Association | Diabète Quèbec, 2011).

2.5.4 Complications associated with diabetes
Apart from the usual symptoms of diabetes discussed above, there are numerous complications
that manifest in response to hyperglycemic states. These complications can be grouped into two
main categories: macrovascular complications, and microvascular complications.
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Macrovascular complications
The macrovascular complications associated with diabetes refer to conditions that arise in
response to damage to the large blood vessels. This damage is largely due to atherosclerosis, the
process of plaque build-up in the arterial walls that eventually leads to the narrowing and
blockage of arteries (Fowler, 2008). As a result, individuals with diabetes are at an increased risk
of numerous adverse cardiovascular events (Diabetes Canada, 2018b). The blockage of arteries
results in reduced blood flow to all areas of the body. Without adequate blood supply to the
heart, individuals with diabetes can experience chest pain and shortness of breath, both
symptoms of coronary artery disease (Diabetes Canada, 2018b). Furthermore, limited blood
supply to the brain can result in cerebrovascular disease and ischemic stroke (Fowler, 2008).
Once an individual with diabetes experiences a stroke, they are more likely to experience another
one and are at a greater risk of dying from the injury (Fowler, 2008). Lastly, reduced blood
supply to the limbs can result in peripheral artery disease. This disease causes patients to
experience pain in their lower extremities, and, in advanced states, can require amputation to
deal with the resulting pain and infection (American Diabetes Association, 2003).

While there is substantial evidence to suggest that these complications can be avoided with
appropriate therapy, CDV continues to be the main driver behind the devastating disability and
premature death experienced by individuals with diabetes (Diabetes Canada, 2018b). In fact,
according to Diabetes Canada, “diabetes confers a CVD event risk that is equivalent to aging
approximately 15 years” (Diabetes Canada, 2018b).

Microvascular complications
Microvascular complications arise in response to damage to the small blood vessels. While less
common than macrovascular complications, these conditions are severe, and, if improperly
managed, can be fatal. Retinopathy has been hypothesized to be the most common microvascular
complication experienced by individuals with diabetes (Fowler, 2008). This condition is caused
by damage to the retina and results in visual impairments, including blindness (Fowler, 2008;
WHO, 2019). Signs of retinopathy may be apparent before a definitive diabetes diagnosis is
made; however, the majority of cases begin to manifest as the number of years lived with
diabetes increases and if poor glycemic control is present (Fowler, 2008). Unfortunately,

31
retinopathy is often completely asymptomatic and therefore requires routine yearly eye
examinations. Diabetes related nephropathy is another microvascular complication associated
with diabetes that results from injury to the small blood vessels of the kidney (WHO, 2019). This
condition is characterized by high levels of protein in the urine and usually causes patients to be
asymptomatic in its early stages (WHO, 2019). However, if left untreated, nephropathy can lead
to kidney failure and eventually death (WHO, 2019). Lastly, diabetes related neuropathy results
from hyperglycemic-induced nerve damage and causes a wide variety of symptoms that differ
according to the type of affected nerves (WHO, 2019). Symptoms can vary from numbness in
extremities, to foot ulceration, to impotence in men (Fowler, 2008; WHO, 2019). Neuropathy, if
untreated, can result in lower-limb amputation (WHO, 2019). In fact, it is estimated that greater
than 80% of all amputations result from symptoms associated with diabetes related neuropathy
(Fowler, 2008).

2.5.5 Treating diabetes
To standardize the treatment of diabetes across Canada, Diabetes Canada has published six sets
of guidelines to provide a comprehensive summary of the current literature to guide care
(Diabetes Canada, 2018b). These documents were designed as a tool to educate health care
providers to close the gap between what is known and what is done in terms of caring for
individuals with diabetes (Diabetes Canada, 2018b). The guidelines provide recommendations
for, and an in-depth explanation of, the treatment of diabetes, addressing the direct effects of
diabetes, and mitigating the risk factors for other complications. As referenced in section 2.5.4,
cardiovascular complications associated with diabetes are responsible for the greatest symptom
burden experienced by individuals with diabetes, with their ability to cause substantial disability
and premature death (Diabetes Canada, 2018b). Accordingly, Diabetes Canada has put the
management of cardiovascular risk factors at the forefront of their care plan (Diabetes Canada,
2018b). They believe that aggressive management of CVD risk factors is necessary for all
individuals living with diabetes, and summarize their treatment recommendations into the
“ABCDES of diabetes care” (Diabetes Canada, 2018 b). These recommendations incorporate both
pharmacologic and lifestyle management strategies to address the most serious complications
associated with diabetes (Diabetes Canada, 2018b). There is no particular order in which these
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targets should be addressed. Rather, the health care provider must make a plan for each
individual patient, with the eventual goal of reaching as many targets as possible.
The first guideline involves controlling blood glucose levels (Diabetes Canada, 2018 b). The “A”
refers to hemoglobin A1C levels, which represent the amount of sugar in the blood (Diabetes
Canada, 2018b). The target is A1C levels less than 7%, which may be managed differently based
on the type of diabetes (Diabetes Canada, 2018b). While it is recommended that individuals with
T1DM maintain their blood glucose levels by taking daily insulin injections, the first-line therapy
for individuals with T2DM is oral doses of metformin (Diabetes Canada, 2018b). In instances in
which the combination of metformin and lifestyle changes is unable to adequately manage
T2DM, then second-line therapies, such as dipeptidyl peptidase-4 inhibitors and insulin
secretagogues, are recommended (Diabetes Canada, 2018b).
The second guideline involves the management of high blood pressure, “B” (Diabetes Canada,
2018b). The BP target for individuals with both T1DM and T2DM is the same: less than 130/80
mmHg (Diabetes Canada, 2018b). This target can be achieved with a variety of antihypertensive
medications; however, an angiotensin-converting enzyme (ACE) inhibitor or angiotensin
receptor blocker (ARB) is generally recommended as first-line therapy for individuals with
diabetes presenting with elevated BP and cardiovascular risk factors (Diabetes Canada, 2018b).
In addition to their BP lowering abilities, ACE inhibitors and ARBs have additional renal
protective effects, giving them the title of first choice agents (Diabetes Canada, 2018b). If BP is
unable to be controlled with one of the aforementioned agents along with lifestyle management,
combination therapy involving two or more antihypertensives may be recommended (Diabetes
Canada, 2018b). Studies by the UK Prospective Diabetes Study Group (1998) suggest that more
than one antihypertensive agent is often required. Additional therapies include thiazides,
thiazide-like diuretics, and dihydropyridine calcium channel blockers (Diabetes Canada, 2018b).
The “C” represents controlling cholesterol levels to treat dyslipidemia, a condition that affects
numerous individuals with diabetes (Diabetes Canada, 2018b). While the risk of CVD is elevated
in all individuals living with diabetes, irrespective of their cholesterol levels, those with elevated
cholesterol levels are at an even greater risk of complications (Diabetes Canada, 2018b). Experts
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recommend that levels of low-density lipoprotein cholesterol, known as the “bad cholesterol”, be
less than 2.0 mmol/L (Diabetes Canada, 2018b). To achieve this target, treatment with statins is
generally recommended (Diabetes Canada, 2018b). When low-density lipoprotein cholesterol is
not lowered to target with statin therapy, second-line agents, such as ezetimibe and evolocumab,
may be added to the individual’s treatment regimen (Diabetes Canada, 2018b).
The “D” in the ABCDES approach represents “Drugs to protect your heart”, and provides a
comprehensive summary of the pharmacologic management of the CVD risk factors mentioned
above (Diabetes Canada, 2018b). A combination of blood glucose-lowering medications, BPlowering drugs, and cholesterol-lowering agents is recommended to prevent cardiovascular
events (Diabetes Canada, 2018b). This step highlights the common need for pharmacologic
agents in addition to lifestyle changes.
The next guideline, the “E”, outlines two lifestyle management strategies that can have a
considerable impact on the course of the disease: exercise and eating (Diabetes Canada, 2018b).
Maintaining a healthy body weight by engaging in regular exercise and consuming a healthy diet
are vital to adequate diabetes management (Diabetes Canada, 2018b). The current literature
recommends that, to achieve health benefits, a weekly plan of 150 minutes of aerobic activity
plus two sessions of resistance training per week is required (Diabetes Canada, 2018b). In terms
of diet, researchers strongly recommend that individuals with diabetes consult a registered
dietician to determine the most appropriate dietary changes to mitigate their individual risk
factors (Diabetes Canada, 2018b).
The “S” encompasses two habits that can negatively impact diabetes management: stress and
smoking (Diabetes Canada, 2018b). It has been reported that individuals who smoke have poorer
glycemic control, as well as an increased risk of myocardial infarction, stroke, and end stage
renal disease (Diabetes Canada, 2018b). Accordingly, Diabetes Canada recommends that
individuals with diabetes quit smoking to reduce their risk of complications (Diabetes Canada,
2018b). Furthermore, individuals experiencing high levels of stress may be unable to adhere to
their care plan and thus are more likely to experience poor glycemic control (Diabetes Canada,
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2018b). Engaging in regular exercise and calming activities, such as yoga, are therefore
recommended (Diabetes Canada, 2018b).

2.5.6 Barriers to optimal diabetes management
While the ABCDEs approach to caring for diabetes seems straightforward, the evidence suggests
that numerous factors prevent individuals from achieving optimal care. Researchers have
attempted to quantify these barriers to care, both in terms of barriers at the patient level as well
as barriers to optimal physician performance. Since the present study is addresses a physiciancontrolled behavior, the discussion will be limited to barriers at the physician level. However,
numerous barriers exist at the patient level, including misconceptions about perceived sideeffects, missed medication doses due to illness or a change in routine, and non-compliance with
diet and lifestyle modifications (Harris et al., 2005; Grover et al., 2014).
Therapeutic or clinical inertia, defined as the “failure of providers to begin new medications or to
increase dosages of existing medications when an abnormal clinical parameter is recorded”, has
been proposed as a barrier to achieving proper diabetes management (Okonofua et al., 2006).
Practitioners caring for individuals with diabetes often adopt a “treat to failure” strategy, rather
than “treating to success” strategy, meaning they are often reluctant to alter treatment regimens
until the patient presents with advanced symptoms (Brunton, 2019). A study among physicians
treating patients with elevated blood glucose (A1C>7.5%) revealed the following results: “it took
[physicians] an average of 1.9 years to intensify treatment by one agent, 7.2 years to add a
second agent, and 6.1 years to intensify with a third oral antidiabetic drug” (Brunton, 2019). The
causes of therapeutic inertia are widespread and vary based on the individual health care
provider. However, researchers believe that overestimating the quality of care that they provide
to their own patients, as well as finding justifications to avoid treatment intensification (i.e.
assuming that their patient will have poor adherence to the new drug), and a lack of knowledge
of changing scientific understandings of best care likely all contribute to the commonality of this
barrier to care (Harris et al., 2005). The slow integration of guidelines into practice prevents
patients from benefiting from novel therapies and treatments.
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Concomitant medical and mental health concerns challenge a physician’s ability to provide
adequate diabetes care (Booth et al., 2012). The relationship between diabetes and mental health
disorders is well documented (Diabetes Canada, 2018b). Accepting a diabetes diagnosis can be
challenging, as the proper management requires a lifelong commitment. The burden of
continuous monitoring and treatment can give rise to numerous negative feelings, such as anger,
frustration, guilt, and depression (Diabetes Canada, 2019a). Individuals who experience these
feelings for prolonged periods are at a greater risk of developing psychiatric disorders. In fact,
individuals with diabetes experience mental health disorders, specifically depression, at a higher
rate than the general population (Canadian Diabetes Association, 2008; Booth et al., 2012). It is
estimated that the prevalence of depressive symptoms and major depression among individuals
with diabetes is 30% and 10%, respectively (Diabetes Canada, 2018b). Apart from the burden
associated with the symptoms of psychiatric disorders, studies have shown that pharmacological
treatments for mental health disorders can pose a threat to the health of individuals with diabetes
(Diabetes Canada, 2018b). Weight gain, poor glycemic control, and changes to lipid profile have
been associated with certain medications (Diabetes Canada, 2018b). As a result, caring for these
competing medical concerns becomes challenging. A study among diabetes patients in Ontario
revealed that these competing concerns pose a challenge to both individuals and their health care
providers (Booth et al., 2012). While individuals living with diabetes and a mental health
disorder have greater difficulty managing their symptoms and adhering to treatments, their
practitioners are confronted with competing issues that makes designing appropriate diabetes and
CVD treatment plans challenging (Booth et al., 2018).
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Chapter 3
3

Methodology

This chapter provides an overview of the research methodology, starting with the study design in
section 3.1. Section 3.2 discusses the advantages and disadvantages of using administrative data
to conduct health research. The following section, 3.3, provides an overview of the OPEM
programme, focusing specifically on the first trial replicate. Participant selection is then
discussed in section 3.4, followed by the data sources in section 3.5. Section 3.6 describes the
study variables, and the last section, 3.7, covers the statistical analyses.

3.1 Randomized controlled trials
It has long been accepted that the RCT is the “gold-standard” for clinical research evaluating the
effect of an intervention. This design, in its simplest form, involves following two groups of
participants over time to observe whether outcomes differ between groups. By employing
randomization techniques to assign participants to experimental and control groups, all factors
besides the intervention itself tend to be balanced across groups. Many of the biases inherent in
other study designs are minimized by the randomization process; thus, RCTs provide strong
grounds on which causal mechanisms can be established.

3.1.1 Pragmatic randomized controlled trials
Historically, most RCTs have not been designed with an awareness that they can serve either one
of two purposes, and that a trial is best designed with an awareness of these two alternative
purposes (Schwartz & Lellouch, 1967). “Explanatory” trials aim to optimize their ability to
detect a mechanism of action and often require controlled conditions to ensure that the outcome
is a direct result of the exposure of interest (Schwartz & Lellouch, 1967). “Pragmatic” trials, on
the other hand, aim to generate results that will assist in decision making processes and are
therefore conducted in routine, “real-world”, settings (Schwartz & Lellouch, 1967). Other
researchers have used the concepts of efficacy and effectiveness as a parallel to explanatory and
pragmatic trials (Singal et al., 2014).
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The answer to the question “what makes a trial pragmatic?” is neither simple nor succinct. To aid
in trialists’ understanding of the correlates of pragmatism, Thorpe et al. (2009) designed the
Pragmatic-Explanatory Continuum Indicator Summary wheel, commonly referred to as PRECIS.
This tool highlights 10 key domains to consider while designing a trial to ensure that the design
matches its intended purpose (Thorpe et al., 2009). Elements to consider when designing a
pragmatic trial include the selection of a wide range of participants, selecting outcomes that are
clinically relevant to participants, and using “usual practice” as a comparison group, among
many more (Thorpe et al., 2009). The authors of this tool agree with the assertion by Schwartz
and Lellouch that the design of a trial is rarely purely pragmatic or purely explanatory; as the
tools name suggests, trials instead lie on a continuum (Thorpe et al., 2009). As a result, trialists
must optimize design choices that will facilitate the application of results to their intended
setting.

PRECIS became a widely recognized tool for designing trials that match their intended purpose,
and thus was referenced in numerous papers (Loudon et al., 2015). With this awareness came
feedback from trial investigators to improve the tools function (Loudon et al., 2015).
Accordingly, in 2015, the authors published a revised version of the tool, named PRECIS-2, that
was designed to address the identified weaknesses (see figure 3.1) (Loudon et al., 2015). While
maintaining the original wheel format, the updated form revised its components to include the
following nine domains: eligibility criteria, recruitment, setting, organization, flexibility
(delivery), flexibility (adherence), follow-up, primary outcome, primary analysis (Loudon et al.,
2015). Furthermore, a scoring system was introduced whereby domains that are very explanatory
receive a score of 1, while those that are very pragmatic are given a score of 5 (Loudon et al.,
2015).
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Figure 3.1: The PRECIS-2 wheel.

Data source: Loudon et al. (2015)

The value in designing pragmatic trials to conduct health-related research is clear. While all
well-conducted RCTs generally achieve high internal validity, traditional RCTs have been
criticized as lacking in external validity (Patsopoulos, 2011). Strict inclusion and exclusion
criteria, blinding, and optimized conditions, which enable the trial to focus on a mechanism of
action, make the trial so different from the usual care in the setting in which the trial was actually
conducted, let alone from the settings in which the results are intended to be applied, that using
its findings to make decisions in a real-world setting is challenging (Patsopoulos, 2011).
Pragmatic trials attempt to overcome this barrier by designing trial conditions that mirror
everyday practice. As a result, the direct application of findings from pragmatic trials to
decision-making processes by clinicians, policymakers, or patients in usual care in the setting in
which the trial was conducted and other similar settings is facilitated. Health care policy makers
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are increasingly demanding that researchers provide high-quality, generalizable evidence to
inform decision making processes (Patsopoulos, 2011). Pragmatic trials aim to do just this.

3.1.2 Cluster randomized controlled trials
Cluster randomized controlled trials (cRCTs) are a form of RCT where random assignment is at
the “cluster” and not the individual level. Clusters may be families, physician practices or even
entire communities. Reasons for using cRCTs include avoiding contamination between
intervention groups, factors related to how the interventions are applied (e.g. physician education
programs are naturally applied at the practice level) or out of ethical concerns. cRCTs are
typically more pragmatic in nature than are traditional, individual-RCTs, as they are equipped to
study different approaches to patient care and, as a result, generate results of importance to
healthcare decision makers (Cook et al., 2016; Ford & Norrie, 2016). To account for clustered
data, more advanced statistical methods are required (see section 3.7.3).

3.1.3 Factorial randomized controlled trials
While traditional RCTs are designed to study a single intervention, factorial RCTs are designed
to study two or more interventions simultaneously. In a trial investigating two unique
interventions (referred to as a 2x2 factorial trial), participants are randomized to one of four
groups: intervention A alone, intervention B alone, intervention A and intervention B, or neither.
The goal of factorial trials is to achieve “two [or more] trials for the price of one”; thus, one must
assume that the effect of intervention A is unchanged in the presence of intervention B (no
interaction) (Cipriani & Barbui, 2013). Results are therefore reported as if they were obtained
through two independent trials investigating the effect of intervention A and intervention B
(Cipriani & Barbui, 2013). Section 3.7.2 discusses the analysis of factorial RCTs.

3.2 Implications of using administrative data in health research
Health administrative databases capture all information gathered during routine care visits,
including, but not limited to, vital statistics, demographic information, claims, and clinical
documentation (Cowie et al., 2017). As health administrative databases have become
increasingly common in the medical community, they have been utilized as the primary data
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source for many clinical studies. Health administrative databases have particularly facilitated the
conduct of studies on large populations, and among hard-to-reach individuals (Harron et al.,
2017). However, these studies do not replace traditional studies that employ primary data
collection techniques (Harron et al., 2017). As a result, the benefits of using health administrative
data as the basis of a research study must be weighed against the drawbacks before carrying out
the study (see table 3.1).

Table23.1: The potential advantages and disadvantages to using health administrative data as the
main data source for research.
Advantages

Cost and ease1
No recruitment and follow-up procedures
Reduced participant burden
Participants do not have to repeat information previously shared
Near-universal coverage1
Captures individuals normally hesitant to participate in research
Prevents differential non-response and attrition bias
Long-term availability1
Regularly collected data allows for outcome measurement over long
periods of time
Accuracy1
Detailed information available on complex and difficult to remember
events
Disadvantages Data quality2
Coding errors
Data validation2
Lack of validated and generalized tools for measuring data quality
Data privacy and security2
Consent and ethics approval
Timeliness of data access2
May be a delay between when data is collected and when data is
approved for research purposes
Missing data3
Occurs when reporting is incomplete and when subjects choose not to
interact with the health care system
Problems with data linkage3
Insufficient identifying information can prevent databases from being
linked to ascertain exposure and outcome variables
Data sources: 1 Finkelstein A & Taubman (2015); 2 Cowie et al. (2017); 3 Harron et al. (2017)
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3.3 The OPEM programme
The OPEM research programme consisted of three individual trials (replicates) that shared a
common objective: to investigate the ability of printed educational materials (PEMs), referred to
in the OPEM protocol as “printed educational messages”, to addresses evidence-to-practice gaps
pertaining to diabetes and hypertension care delivered in primary care settings (Zwarenstein et
al., 2007). The three replicates were designed as pragmatic, 2x2 factorial, cRCTs. The protocol is
registered under ISRCTN72772651.

The ultimate goal of the OPEM programme was to improve patient outcomes by reducing
complications associated with diabetes and hypertension (Zwarenstein et al., 2007). To achieve
this goal, health care providers must be well educated and informed on the most current, and
relevant, guideline recommendations. Accordingly, the interventions were directed at FP/GPs.
To prevent contamination, physicians who work in group or shared practices were identified by
common address and were randomized using a random number generator, omitting stratification,
to receive the same intervention (Zwarenstein et al., 2007). As a result, randomization occurred
by cluster at the group practice level, rather than at the individual FP/GP level. Group practices
also allow for patients to be seen by more than one physician; therefore, patients who received a
prescription written by any Ontario FP/GP throughout the study period qualified for inclusion,
even if the physician wasn’t their primary care provider (Zwarenstein et al., 2007). Since
administrative data was used to ascertain all baseline and outcome measurements, both FP/GPs
and patients were blinded to the conduct of the trial.

The programme spanned a nine-month period, with the first replicate delivered in January of
2005 and the second and third replicates delivered three and six months later, respectively. The
replicate that pertains to this study is the first replicate, focusing on treatment intensification for
diabetes care. The objectives of this replicate, as discussed in section 1.3, were to evaluate the
effect of two separate versions of a PEM (insert, and outsert) and their interaction on physician
adherence to guidelines for the prescription of drugs used to reduce the risk of cardiovascular
complications associated with diabetes. Namely, the PEMs recommended that at least two
antihypertensives, one of which is an ACE inhibitor and another that is considered, in this study,
to be an “other” antihypertensive (i.e. ARB, beta-blockers, calcium channel blockers, diuretics),
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and a cholesterol-lowering agent, be prescribed. Moreover, we aimed to determine whether the
recency of diabetes diagnosis impacted the likelihood of adhering to guidelines, as well as the
physician characteristics that are associated with engaging in treatment intensification.

Figure 3.2 provides a timeline of events for the study. To determine whether the intervention was
effective, a baseline look at prescribing habits was required to be able to compare treatment
regimens pre-intervention and post-intervention. All of the information required to answer the
research questions was available in administrative databases held at ICES; therefore, primary
data collection techniques were not employed. The details of the data collected are provided in
section 3.5.
Figure 3.2: Timeline for the OPEM trial focusing on diabetes treatment intensification.
PEM mailing date: January 15th, 2005

Pre-intervention period:
January 15th, 2004 – January 14th, 2005

Follow-up period:
January 16th, 2005 – January 15th, 2006

3.3.1 Ethics
The OPEM programme was approved by the Research Ethics Board at Sunnybrook Health
Sciences Centre and the Women’s College Health Sciences Centre in Toronto, Ontario
(Zwarenstein et al., 2007). ICES is approved by Ontario’s Information and Privacy
Commissioner under section 45 of Ontario’s Personal Health Information Protection Act to
analyze routinely collected health data while insuring the privacy of the individual patients
(ICES, 2020). Because all study outcomes were measured using ICES data, informed consent
from the physicians and the patients was not required. The decision to waive informed consent
would be now supported by The Ottawa Statement on the Ethical Design and Conduct of Cluster
Randomized Trials on the grounds of posing no more than minimal risk to study participants
(Weijer et al., 2012). All data is encrypted; therefore, neither individual patients, nor physicians,
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can be directly or indirectly identified provided that small cells (<6) are suppressed. Since this
project involves the analysis of data from several years ago, we sought and received approval
from the College of Physicians and Surgeons of Ontario to re-link their data on physician
identifiers to the administrative databases held at ICES.

3.3.2 Setting
The study was carried out in Ontario, Canada. All FP/GPs practicing within the province who
met the inclusion criteria (see section 3.4.1) were included in the study. Ontario residents are
eligible to access the majority of health care services at no cost as a result of a publicly funded
health care system, OHIP. Among the list of qualifying services is visits to a family doctor.
Accordingly, all Ontario residents who meet the criteria for OHIP are permitted to seek care
from a family doctor, irrespective of their financial status, and were therefore eligible to
participate in the study.

3.3.3 informed
informed was a peer-reviewed practice synopsis that provided an overview of the latest research
findings to promote EBM (Zwarenstein et al., 2007). The 8-page issues were developed using
expertise from both clinical and research staff at ICES (Zwarenstein et al., 2007). The first
edition of informed was released in 1994, and publication continued quarterly until ceasing in
2007 (Zwarenstein et al., 2016). Subscription to informed was free and voluntary for all PCPs in
Ontario, and approximately 15,000 PCPs subscribed throughout the 13-year period (Zwarenstein
et al., 2007).

Despite the large list of subscribers, the effectiveness of informed remained unknown until a
sample of 500 Ontario physicians were surveyed in 1997 (Kelsall, 2005). The results revealed
that 71% of the physicians had received informed, and, among these, 89% reported that the
information was useful and 53% reported reading at least the majority of the issues (Kelsall,
2005). Additional surveys revealed that physicians considered informed to be a “respected and
valued source of information” (Kelsall, 2005).
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The OPEM programme utilized the reach of informed, and its reputation, to deliver the
intervention. A communications consultant assisted in the design of the PEMs, while a diverse
team of physicians was consulted to ascertain the barriers to implementing new evidence in their
practice (Zwarenstein et al., 2007). The PEMs came in two different forms: a short, directive
message (outsert), and a long, detailed message (insert) (see Appendix 3, 4A, and 4B). The
outsert was printed on a postcard sized paper, and was attached to the front page of informed in
the bottom left corner (Zwarenstein et al., 2007). Bright colors and large font sizes were used to
attract the eye of the reader. The main recommendations to prescribe more than one
antihypertensive, one of which is an ACE inhibitor, and a cholesterol-lowering agent are clearly
highlighted on front side of the outsert, while the back side provides a brief explanation for the
recommendations, as well as a link to obtain more information. The alternative intervention
against which the insert was compared was a two-page, more traditional narrative review article
that was designed to look like the rest of the articles in that edition of the newsletter, but covered
a topic (intensification of treatment for diabetes) that was not covered elsewhere in the edition
(Zwarenstein et al., 2007). Similar to the outsert, the insert also made use of bright colors and
graphics to attract readers. The article guides readers through the “A-B-Cs” of diabetes
treatment, with one section for each of the three recommendations. Each section highlights the
recommendation and gives an in-depth explanation for the evidence behind this
recommendation. The article ends with a section entitled “The Bottom Line” that summarizes the
main points, similar to the outsert.

3.3.4 Pragmatism of the trial
The design elements of the OPEM trial for diabetes treatment intensification were assessed using
the PRECIS-2 tool (see table 3.2 and figure 3.3). The extent to which the trial mimics routine
practice suggests that the design elements are highly pragmatic, chosen to maximize the trials
applicability. The one design element that may raise doubt among readers is the choice to
exclude patients under the age of 66 despite being eligible for the medications in usual care. This
decision was made in response to the availability of data at ICES, as prescriptions for those
under 66 are generally not covered by the Ontario Drug Benefit (ODB) program and are thus not
captured in the databases. Moreover, since the primary objective of the study was to measure the
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effectiveness of an intervention aimed at physicians, and not patients, this choice is justified.
Therefore, overall, the design elements of the trial agree with its intended purpose.
Table 3.2: PRECIS-2 components of the OPEM trial for diabetes treatment intensification.
PRECIS-2 domain
Eligibility

Recruitment

Setting

Organization

Flexibility: delivery

Flexibility: adherence
Follow-up

Primary outcome

Primary analysis

Score Explanation
4
Physicians: Almost all Ontario FP/GPs in active
practice during the trial period
Almost all individuals 66 and above with type 1 and
type 2 diabetes in Ontario
5
Physicians and patients identified from administrative
databases held at ICES - no consent required, zero
impact on behavior
5
FP/GP practices across Ontario, Canada – no
exclusions based on geography, staffing levels, patient
population, etc.
5
No additional staff or training required to deliver the
intervention – unobtrusive and feasible to do
unchanged in usual Ontario setting, provided the
ministry or other organization develops and mails the
intervention
5
Guideline recommendations are provided to
physicians in the PEMs, but the choice to prescribe is
ultimately up to the physician – a naturalistic
approach with no restrictions on behavior so would be
identical if implemented as policy
5
No measures in place to monitor whether physicians
receive, open, and read the PEM
5
One-year post intervention mailout by means of
administrative databases - no contact at all with
individual physicians or patients
4
Behavior change among physicians (manifested
through intensification of prescriptions for ACE
inhibitors, “other” antihypertensives, and cholesterollowering agents) – more important to physicians than
to patients
5
Intention-to-treat analysis; no physicians or patients
lost to follow-up
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Figure 3.3 PRECIS-2 wheel for the OPEM diabetes trial.

3.4 Participant selection
Both physicians and their individual patients were included in the study population; as a result,
separate inclusion and exclusion criteria were developed for each group.

3.4.1 Physician selection
Inclusion criteria:
To be eligible to participate, physicians must have been practicing as a fee-for-service FP or GP
in Ontario between August 1st, 2003 and July 31st, 2004 (Zwarenstein et al., 2007). Fee-forservice is a compensation model characterized by the billing of all services to OHIP based on a
standard fee system (ICES, 2006). Both individual physicians and those practicing in group
settings are eligible to be compensated using the fee-for-service model (Ministry of Health &
Long-Term Care, 2020). FP/GPs were chosen to comprise the physician population as they are
responsible for delivering nearly 80% of care for patients with diabetes (Diabetes Canada,
2018b). In 2019, there were only 231 Endocrinologists working in Ontario, compared to the
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14,962 practicing FP/GPs (Canadian Medical Association, 2019b). Accordingly, FP/GPs
continue to take on the primary role in caring for individuals with diabetes.

Exclusion criteria:
Physicians who submitted an additional claim under a different specialty code between August
1st, 2003 and July 31st, 2004 were excluded. In addition, physicians who were not considered to
be in “active” practice in 2004 were excluded. This included those who accumulated less than
$50,000 in fee-for-service billings in 2004, those who prescribed medications to fewer than 100
patients aged 66 and above in 2004, and those who did not prescribe medication to an individual
66 or older in at least 10 of the 12 months in 2004 (Zwarenstein et al., 2016). The latter two
exclusion criteria were used to ensure that the physicians had adequate experience with elderly
patients. Furthermore, physicians who submitted a claim under a speciality other than FP/GP
between January 16th, 2005 and January 15th, 2006, and those who were no longer practicing
during this period, were excluded. Physicians who were not matched to a diabetes patient were
excluded, as were physicians who were missing information on personal identifiers. Lastly,
physicians working in shared practices that were mistakenly sent multiple versions of the PEM
were excluded.

3.4.2 Patient selection
Inclusion criteria:
Patients were considered for inclusion if they had a diabetes diagnosis on or before January 15th,
2004.

Exclusion criteria:
Individuals who were younger than 66 years, had an invalid ICES key number, or were nonOntario residents were excluded. Individuals who did not see an OPEM physician one year prior
to the PEM mailout, or who received an equal amount of services from more than one physician,
were also excluded. Moreover, individuals who did not see a study FP/GP between February 1 st,
2005 and January 31st, 2006 were excluded. Those who filled a prescription for one of the study
drugs (ACE inhibitor, “other” antihypertensive, or cholesterol-lowering agent) that was
prescribed by a non-OPEM physician between January 16th, 2005 and January 15th, 2006 were
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excluded from the analyses. Individuals who died before the intervention was delivered were
also excluded. Lastly, individuals who were matched to a physician with missing data were
excluded.

3.4.3 Linking patients to physicians
All individuals who received a prescription for an ACE inhibitor, “other” antihypertensive agent,
or cholesterol-lowering agent during the lookback period were identified by DIN in ODB. The
prescription(s) closet to January 15th, 2005 (PEM mailout) were identified and the OPEM
physician/physician group that prescribed these drugs was flagged. The patient was then linked
to this physician/physician group. If a patient was not prescribed an ACE inhibitor, “other”
antihypertensive agent, or cholesterol-lowering agent by an OPEM physician during the
lookback period, this patient was linked to the OPEM physician/physician group that provided
the majority of visits for that patient in the lookback year. If more than one physician/physician
group tied for the majority of visits, the patient was excluded from the study.

3.5 Data sources
Seven administrative databases were linked at ICES to ascertain patient and physician
characteristics, treatment regimens for diabetes medications, and the overall effectiveness of the
intervention. To ensure confidentiality, patients were stripped of personal identifiers and were
assigned a unique 10-digit ICES Key Number that was used to connect the patient’s
demographic information to the health services they received. Similarly, physicians were
identified by an encrypted physician number that was used to link information about the
individual care provider with the services they provided.

Ontario Drug Benefit Claims (ODB):
The ODB program is a publicly funded system that provides a wide range of prescription drugs
to qualifying individuals in Ontario, including those 65 years and older. This database was used
to quantify prescriptions of ACE inhibitors, “other” antihypertensives, and cholesterol-lowering
agents to those 66 and older during the pre-intervention period, and throughout follow-up.
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Ontario Health Insurance Plan Claims Database (OHIP):
The OHIP database contains information on the inpatient and outpatient services that are
publicly funded for Ontario residents. This database was used for cohort creation by identifying
individuals who were eligible for inclusion. The OHIP database was used to identify patients
who did not see a FP/GP during the pre-intervention period, as well as those who did not attend
an appointment during follow up. Moreover, physicians who did not submit at least one claim as
a FP/GP during the pre-intervention period, or during follow-up, were identified and excluded.

Corporate Provider Database (CPDB):
The CPDB contains demographic, specialty, eligibility, and practice location information for all
physicians funded by the Ministry of Health. This database was used to identify physician
characteristics at baseline to produce descriptive statistics. The characteristics that were obtained
from CPDB were physician age, sex, and years in practice. Furthermore, CPDB was used to
identify and exclude physicians no longer practicing in the pre-intervention and follow-up
periods.

ICES Physician Database (IPDB):
The IPDB contains information on both demographic and professional characteristics of all
Ontario physicians. The characteristics that were obtained from IPDB were practice location
(Northern/Southern, and rural/non-rural), visits per year, total billings per year, and location of
medical school. This database was also used to ensure that the physicians included in our study
practiced in office-based care; FPs working in areas such as sports medicine or psychotherapy
were excluded.

Registered Persons Database (RPDB):
The RPDB houses information on basic patient demographics, received from the Ministry of
Health, for all Ontarians with a health card number. This database was used to obtain
information on patients age and sex at baseline. In addition, RPDB was used to exclude nonOntario residents, and those who died during the pre-intervention period.
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Drugs List - Drug Identification Number (DIN):
The DIN database was used to characterize the prescription drugs identified through ODB. Each
prescription drug that has been approved for use in Canada has an 8-digit drug identification
number (DIN). The DIN database was used to obtain information on each medications DIN, drug
name, drug group, route of administration, and strength.

Ontario Diabetes Database (ODD):
The ODD contains information on incident and prevalent cases of diabetes in Ontario. This
dataset was used to build our cohort of patients. Only those with a diagnosis date on or before the
beginning of the pre-intervention period (August 1st, 2003) were included. In addition, the
diagnosis date available in the ODD was used to create the variable “years since diagnosis” to
guide a subgroup analysis.

3.6 Study variables
3.6.1 Intervention
The intervention variable is the PEM delivered with informed, discussed in detail in section
3.3.3. We were interested in determining whether the ability of a PEM to influence physicians to
intensify their patient’s treatment regimens depended on the format of the message, and therefore
studied two distinct PEMs: an insert, and an outsert. Thus, due to the 2x2 factorial design, FP/GP
groups had the opportunity to be assigned to one of four intervention groups: informed alone
(control), informed + insert, informed + outsert, informed + insert + outsert. The rationale for
choosing this intervention is clearly highlighted in section 2.4.1: the conflicting, and poor
quality, evidence for the effectiveness of PEMs has caused researchers to question the use of this
common KT strategy within the health care field.

3.6.2 Outcomes
The goal of the study was to determine whether PEMs are effective at prompting FP/GPs to
intensify their patient’s treatment regimens. Thus, the outcome was measured at the patient level.
In the context of diabetes care, one of the ways in which this behaviour change manifests is
through treatment intensification efforts. The literature suggests that a single definition for
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treatment intensification, even within the realm of diabetes care, does not exist. However, one
characteristic of treatment intensification that appears to be consistently incorporated in all
definitions is the addition of a new (i.e. not previously prescribed) antidiabetic agent to the
patient’s treatment regimen (Fu & Sheehan, 2016; Desai et al., 2018; Arnold et al., 2018;
Canivell et al., 2019). Moreover, any increase in the dose of antidiabetic medications was also
considered by Arnold et al. (2018) to qualify as treatment intensification. Canivell et al. (2019)
listed the lack of medication dose information in their data as a limitation to their study, as they
were unable to identify and include in the treatment intensification group patients who
experienced a dose titration of their current medication.

Our definition of treatment intensification was developed based on a combination of criteria
available in the literature and will be discussed in further detail below. The decision to focus on
ACE inhibitors, “other” antihypertensives (i.e. ARBs, beta-blockers, calcium channel blockers,
diuretics, etc.), and cholesterol-lowering agents stemmed from preliminary research that revealed
that prescription rates for each of these drug classes was below standard by at least 30%
(Zwarenstein et al., 2007). Moreover, the Clinical Practice Guidelines that were available at the
time of the trial recommended all of ACE inhibitors, “other” antihypertensives, and cholesterollowering agents to promote vascular protection in all individuals with diabetes (Canadian
Diabetes Association, 2003). Lastly, we focused solely on antihypertensives and cholesterollowering agents since, at the time of the trial, these drug classes had been shown to significantly
reduce CVD complications and death among diabetes patients (UK Prospective Diabetes Study
Group, 1998; Heart Protection Study Collaborative Group, 2003).
All outcome definitions included only ACE inhibitors, “other” antihypertensives, and
cholesterol-lowering agents that are administered orally. Since our study aimed to target
prescription rates among PCPs, we excluded intravenous therapies, as these are likely to be
administered in hospital by a non-FP/GP. Moreover, ophthalmic solutions were excluded, as
these medications are often prescribed to treat conditions other than the ones of interest in our
study. Glucose-lowering therapies, such as insulin, were also excluded since the study aimed to
target therapies used to prevent complications associated with diabetes, rather than those used to
treat hyperglycemia. All doses were recorded in milligrams.
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Primary outcome:
Objectives one through three are described by the primary outcome. We defined the primary
outcome as the treatment intensification of medications used for controlling the cardiovascular
complications associated with diabetes. The outcome is a composite outcome due to the fact that
intensification could have occurred in any one of the drug classes. A FP/GP is considered to have
intensified their patients treatment regimen if they engaged in one of the following behavior
changes: added a new drug, either an ACE inhibitor, “other” antihypertensive agent, or
cholesterol-lowering agent to their patients treatment regimen, or increased the dose of a current
ACE inhibitor, “other” antihypertensive agent, or cholesterol-lowering agent. An individual’s
baseline treatment regimen was defined as all of the drugs prescribed within the three drug
classes (ACE inhibitor, “other” antihypertensive agents, and cholesterol-lowering agents) during
the lookback period that the individual was still taking at the end of the lookback period. All
drugs prescribed during the follow-up period were recorded. A drug addition occurred when the
number of drugs prescribed was greater in follow-up than at baseline. A dose increase occurred
when the dose of a drug prescribed during the follow-up period was higher than the dose of the
same drug prescribed at baseline.

Our decision to only include drug additions and dose increases as intensification came from both
the definitions used in previous studies, as well as our personal judgement. We believe that any
drug addition or titration that was captured in our study had a high probability of occurring in
response to our intervention, as opposed to other reasons, such as patient side effects.

Secondary outcomes:
We developed a broader definition of treatment intensification as a secondary outcome to
explore objectives one and two (insert and outsert effect) further. While we were confident that
drug additions and titrations observed within our study population likely occurred in response to
our intervention, we approached drug switches with less certainty. Since our PEMs focused on
additions in certain drug classes, but did not directly recommend specific drug names, we had
less confidence in concluding that physicians who switched their patients’ medications did so in
response to the PEM. Drug switches can occur for many reasons, such as patient preference,
physician preference, pharmaceutical company influence, and patient side-effects. However,
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since our PEM specifically recommended that all patients receive an ACE inhibitor, those who
were taking “other” antihypertensives at baseline may have been switched to an ACE inhibitor in
response to the PEM. As a result, we have included medication switches in our composite
secondary outcome measurement to capture FP/GPs who intensified their patient’s treatment
regimen by making a drug switch. The secondary outcome is thus defined as the addition of an
ACE inhibitor, “other” antihypertensive agent, or cholesterol-lowering agent, an increase in the
dose of a current ACE inhibitor, “other” antihypertensive agent, or cholesterol-lowering agent, or
the switch from one drug to another drug across all drug classes. Drug additions and dose
increases were defined previously (see primary outcome). A switch occurred if the total number
of drugs prescribed at baseline was less than or equal to the number of drugs prescribed during
follow up, but at least one drug name differed between the two time periods. Switches were
captured across the three drug classes.

While the primary outcome focused on the intensification of medications across three drug
classes, we were also interested in determining whether this intensification occurred to a greater
extent in certain drug classes. Accordingly, we repeated the primary outcome measurement for
individual drug classes, specifically ACE inhibitors, “other” antihypertensive drugs, and
cholesterol-lowering agents.

3.7 Statistical Analysis
All statistical analyses were conducted using SAS Enterprise Guide 7.1. Analyses followed the
recommendations set forth by the CONSORT extension for cRCTs (Campbell et al., 2012). We
deemed two-tailed p-values less than or equal to 0.05 to be statistically significant. Following
standard practice for the analysis of pragmatic RCTs, the primary analysis attempted to follow
intention-to-treat (ITT) guidelines.

3.7.1 Descriptive statistics
Descriptive statistics were generated to obtain an overall understanding of drug use among
individuals with diabetes in Ontario. The number, and percent, of individuals taking an ACE
inhibitor, “other” antihypertensive, cholesterol-lowering agent, and all three, were calculated
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both at baseline and at the end of follow-up. Moreover, characteristics of the patients and the
physicians were explored at baseline. Patient characteristics of interest included age, sex, years
since diabetes diagnosis, and recency of diabetes diagnosis. Due to ICES constraints on student
data access, it was required that patient age be categorized. Thus, the following three categories
were chosen to classify patients by age: 66-74, 75-84, 85+. These categories were selected to
reflect a commonly used grouping of seniors as the “young-old”, “middle old”, and “old-old”,
which has previously been used in studies (Koo et al., 2017; Kingston et al., 2018). Physician
characteristics of interest included age, sex, billings per year, total visits per year, years in
practice, practice location (Northern/Southern, and rural/non-rural), and whether the physician
graduated from a Canadian medical school. To categorize practice location as Northern or
Southern, we used the forward sortation area of the practices’ postal code. Forward sortation
areas beginning with the letter P were considered to be Northern, while all other Ontario postal
codes (beginning with K, L, M, N) were classified as Southern (Wenghofer et al., 2011; Gauthier
et al., 2012).

3.7.2 Analyzing factorial randomized controlled trials
The primary analysis of a 2x2 factorial trial is conducted “at-the-margins” of the table. In the
present study, we were interested in testing the main effects of the insert and the outsert. Thus,
patients who received the insert (irrespective of whether or not they received the outsert) were
compared to patients who received no insert (objective one). Likewise, patients who received the
outsert (irrespective of whether or not they received the insert) were compared to patients who
did not receive the outsert (objective two). However, intensification rates were calculated and
presented for each of the four intervention groups, allowing readers to summarize the data in
their desired format.

While factorial RCTs are typically underpowered to detect an interaction effect, it is common
practice to evaluate and report on the interaction between the interventions (Kahan et al., 2020).
Thus, a model incorporating the interaction between the insert and outsert was fit and the
estimated size of the interaction, confidence interval, and p-value were reported, as per Kahan et
al. (2020) (objective three). Moreover, interactions were also explored for the secondary
outcomes (Kahan et al., 2020).
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3.7.3 Accounting for clustered data
The statistical methods for analyzing conventional RCTs cannot be applied to cRCTs directly
(Austin, 2007). When subjects are grouped into clusters, the outcomes within clusters may be
more highly correlated than the outcomes between clusters (Austin, 2007). The grouping of
patients within a physician’s practice is a common example of clustered data, and clearly
highlights the need to consider correlated data in the analysis (Austin, 2007). Despite receiving
similar formal training, physicians develop unique styles of patient management. Accordingly,
individuals who are treated by the same physician are likely to receive similar diagnoses and
treatment plans, and, as a result, their outcomes are likely to be correlated. Moreover, since
physicians are known to seek answers to their clinical queries from their colleagues (Coumou &
Meijman, 2006), outcomes among patients within group practices are likely to be correlated.
Thus, the OPEM programme randomized at the group practice level. The similarity between
responses within a cluster is termed within-cluster homogeneity, and complicates the analysis of
cRCTs (Austin, 2007).

Several methods have been proposed for analyzing cRCTs with binary outcomes. The choice of
method depends on whether the unit of analysis is at the subject- or cluster-level (Austin, 2007).
In the present study, treatment regimens were measured at the individual patient level; as a
result, the unit of analysis is subjects. One method for analyzing subject-level data is generalized
estimating equations (GEE) (Austin, 2007).

The GEE method for accounting for clustered data was developed by Liang and Zeger in 1986
and has since seen extensive use in the literature (Liang & Zeger, 1986; Wang, 2014). The
premise is that GEE utilizes correlation matrices to estimate the model’s population-averaged
parameters (Wang, 2014). Examples of correlation structures include the exchangeable structure,
autoregressive structure, stationary structure, and unstructured (Vittinghoff et al., 2012).
According to Vittinghoff et al. (2012), it is appropriate to apply the exchangeable structure to
studies in which patients are clustered to their physician, as the patients themselves are
exchangeable, meaning that they cannot be distinguished from one another within a practice. The
exchangeable structure assumes that the correlations within each cluster share a common value
(Vittinghoff et al., 2012).
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The specification of the appropriate correlation structure improves efficiency (Shults et al.,
2009); however, there are methods to account for misspecified correlation structures. While the
estimates of treatment effect are generally fairly accurate, irrespective of the specified model, the
standard errors can be largely inaccurate (Vittinghoff et al., 2012). The consequences associated
with the failure to account for within-cluster correlation in standard error calculations are vast,
including small standard errors, narrow confidence intervals (CIs), and low p-values (Cameron &
Miller, 2015). Robust, or “sandwich”, standard errors are often used in conjunction with GEE to
estimate proper standard errors (Vittinghoff et al., 2012).

Applying the recommendations of Vittinghoff et al. (2012) to cRCTs, we fit logistic regression
models estimated using GEE, with robust standard errors, to ascertain the effectiveness of PEMs.
SAS can accommodate both GEE and robust standard errors in a single command: proc genmod;
thus, this command was used to conduct all analyses.

3.7.4 Primary outcome
Objectives one and two are similar in that they both aim to determine whether a PEM is effective
at intensifying prescribing habits for diabetes treatment; however, objective one focuses on the
outsert, while objective two focuses on the insert. Since we were only interested in determining
whether or not prescription rates intensified, the dependent variable was binary: the physician
either intensified the treatment regimen, or they did not. Accordingly, a logistic regression model
estimated using GEE was fit (see equation 3.1), where p represents the probability of intensifying
the treatment regimen. This model is referred to as the “main effects model” for the remainder of
the thesis. Separate hypotheses were developed for objectives one and two. The null hypothesis
for objective one was that 1=0; in other words, the odds of treatment intensification among
physicians who received the insert were no different than among those who did not receive the
insert. Similarly, the null hypothesis for objective two was 2=0, meaning that the odds of
treatment intensification did not differ between physicians who received the outsert and those
who did not.
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logit(p) = 0 + 1 insert + 2 outsert

(3.1)

insert = 1 if a physician reiceved the insert PEM
insert = 0 otherwise
{
}
outsert = 1 if a physician received the outsert PEM
outsert = 0 otherwise
Testing for an interaction between the insert and the outsert
While the study was not primarily designed to test for interaction, we evaluated the effectiveness
of the insert in the presence of the outsert for exploratory purposes in objective three. A logistic
regression model was fit (see equation 3.2) to test the null hypothesis that 3 is equal to zero,
where p represents the probability of intensifying a treatment regimen.
logit(p) = 𝛾0 + 𝛾1 insert + 𝛾2 outsert + 𝛾3 insert • outsert

(3.2)

insert = 1 if a physician reiceved the insert PEM
insert = 0 otherwise
{
}
outsert = 1 if a physician received the outsert PEM
outsert = 0 otherwise
Adjusted analysis
To account for any imbalance in baseline predictors on the estimated effect of the insert and the
outsert, an adjusted analysis was carried out. The main effects model (equation 3.1) was adjusted
for the following variables: physician age, sex, years in practice, practice location (Northern vs.
Southern, and rural vs. non-rural), country of training, billings per year, and visits per year. This
analysis simultaneously allowed us to determine the effect of each of the aforementioned
variables on the likelihood of treatment intensification.

Subgroup analysis
The fourth objective was to determine whether the intervention effect differed based on the
stability of a patient’s treatment regimen. We hypothesized that among individuals who have
reached clinical stability, both the patient and the physician may be less inclined to alter their
therapeutic regimen to avoid complications. Since the only patient-level data we had available
from the administrative datasets was on the prescription of drugs rather than on actual
consumption, or response to drugs in the form of side effects, we had no indication of how well
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tolerated the medications were. As a result, we used years since diabetes diagnosis as a proxy
measure of the stability of a patient’s treatment regimen. Since there is no established time to a
stable treatment regimen, we combined evidence from the literature with clinical expertise to
predict the amount of time it takes to attain clinical stability. The three- to six-month period is
consistently referenced when treating an individual with diabetes (Diabetes Canada, 2018b).
When treating a newly diagnosed patient, the goal is to have their A1C, BP, and lipid levels at
target within 3-6 months (Diabetes Canada, 2018b). While these targets are achievable with
commonly prescribed medications, achieving target does not equate to achieving clinical
stability. Antihypertensives are, for the most part, fast-acting drugs, and, as a result, patients
generally achieve a stable BP after three to six months (The PROGRESS Collaborative Group,
2001; Patel et al., 2007; Liu et al., 2005). However, attaining a stable lipid profile is a lengthier
process. Colhoun et al. (2004) showed that, while total cholesterol, low-density lipoprotein
cholesterol, and high-density lipoprotein cholesterol tend to stabilize after 6 months on statin
therapy, triglycerides don’t reach a stable level until two years. As a result, we predict that
clinical stability in terms of diabetes treatment is most likely achieved after two years of therapy.
Thus, we classified individuals who had been diagnosed with diabetes for two years or less at
PEM mailout as “recent diagnoses”, while those who had been living with diabetes for more than
two years were considered “non-recent diagnoses”. This classification assumes that therapy is
initiated immediately upon diabetes diagnosis. To determine whether the recently diagnosed
cases were more likely to have their treatment regimen intensified, we first measured the
interaction between the interventions and the recency of diabetes diagnoses. A subgroup analysis
was only carried out if the interaction terms were significant.

Sensitivity analyses
It was of interest to determine whether the effectiveness of the PEMs was altered by patients who
switched providers throughout the study period. For reference, the trial had two arms
(intervention, and control) and four groups (control, insert, outsert, and insert+outsert). Patients
who were linked to a physician receiving the intervention (any of insert, outsert, or
insert+outsert) at the beginning of the study but were prescribed a medication from a physician
randomized to the control arm during follow-up, or vice versa, were flagged as switching
between treatment arms (switcharm). A logistic regression model was fit to measure the primary
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outcome in patients who remained in their original treatment arms (per-protocol analysis). The
process outlined above was repeated for patients who switched between intervention groups
(switchgroup). A patient was said to have switched between groups if they saw a physician
randomized to a different treatment group than the one to which their original physician was
assigned.

3.7.5 Secondary outcomes
The logistic regression model 3.1 was used to explore the secondary outcome definition that
includes switches, and for each of the individual drug classes.

3.7.6 Missing data
A number of variables in IPDB are not mandatory; thus, certain physician characteristics of
interest were not available for all OPEM physicians. Information on two physician personal
identifiers, age and sex, were missing for a small number of physicians (<6). To maintain
confidentiality, it was required that these physicians (and their corresponding patients) be
removed from the dataset. Moreover, less than six physicians had missing data for total yearly
billings and patient visits. These physicians were included in the primary and secondary ITT
analyses; however, they were excluded from the adjusted analysis.
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Chapter 4
4

Results

This chapter summarizes the results of the study, beginning with a description of the physician
and patient selection in section 4.1. Descriptive baseline statistics are provided for both
physicians and patients in section 4.2. The primary and secondary outcomes are presented in
sections 4.3 and 4.4, respectively.
Tables presenting outcomes provide odds ratios (ORs), 95% confidence intervals (95% CIs), and
two-tailed p-values for all comparisons. Attention is limited to ORs and CIs in the main text.

4.1 Physician and patient selection
Among the 10,863 FP/GPs practicing in Ontario between August 1st, 2003 and July 31st, 2004,
5,685 were excluded for reasons outlined in figure 4.1. While 5,178 FP/GPs were randomized to
receive the intervention, a further 221 were excluded; thus, 4,957 FP/GPs were included in the
study, operating in 4,118 unique practices (clusters). There were 946,853 Ontarians living with
diabetes as of January 15th, 2004. After exclusions, 185,526 individuals were retained in the
sample. Seventy-two patients were matched to a physician with missing data; therefore, 185,454
patients were analyzed.
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Figure 4.1: Participant flow chart: physicians and patients
Physicians assessed for inclusion:
10,863 general and family practitioners in
Ontario between August 1st, 2003 and July 31st,
2004 who submitted at least one OHIP claim
during this period.

Excluded (physicians):
• 3,051 prescribed medications to
fewer than 100 patients ≥66 years
old between August 1st, 2003 and
July 31st, 2004, or did not
prescribe medication to an
individual ≥66 years old in at least
10 months
• 2,357 total fee-for-service billings
<$50,000 in 2004
• 277 physicians submitted a claim
under a different specialty code
between August 1st, 2003 and July
31st, 2004 or failed to be
randomized

Randomized: 4,231 practices
and 5,178 FP/GPs in active
practice

•

•
•

33 physicians submitted a claim
under a specialty other than
FP/GP or no longer practicing
between January 16th, 2005 and
January 15th, 2006
147 physicians in groups with
multiple interventions
41 physicians not matched to
diabetes patients and physicians
missing personal identifiers

Patients assessed for inclusion:
946,853 individuals with a diabetes diagnosis
on or before January 15th, 2004.

Excluded (patients):
• 637,625 <66 years old, missing or
invalid IKN, or non-Ontario residents
• 3,254 did not see an OPEM physician
one year prior to index or could not be
assigned to a physician group due to
equal number of services provided by
another physician group
• 63,618 did not see one of the study
FP/GPs between January 16th, 2005 and
January 15th, 2006
• 56,817 filled a prescription for an ACE
inhibitor, hypertension drug, or
cholesterol-lowering agent that was
prescribed by a non-OPEM physician
between January 16th, 2005 and
January 15th, 2006
• 13 died on or before January 15th, 2005

Retained: 185,526 patients
 66 years old who saw an
OPEM physician between
January 16th, 2005 and January
15th, 2006

•

Analyzed: 4,957 physicians working in 4,118 practices serving
185,454 patients with diabetes.

72 patients matched to a
physician with missing
personal identifiers
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4.2 Descriptive statistics
Characteristics of the physicians and the patients at baseline are provided in tables 4.1 and 4.2,
respectively. No clinically meaningful differences were observed for any of these characteristics
across the four groups as a consequence of randomization. Of note, the mean age of physicians in
the study was approximately 52 years. The percent of female physicians was less than 25% in
each group, and approximately 75% of physicians graduated from Canadian medical schools.
Less than 10% of practices were located in Northern Ontario, and approximately 12% of
practices were considered rural. Nearly half of the patients were between 66 and 74 years and
approximately 41% were between 75 and 84; few patients (~10%) were older than 85. Patients
received their diabetes diagnosis, on average, seven years prior to the study; thus, few were
considered “recent cases”.

Each FP/GP group (cluster) had, on average, 1.2 working FP/GPs (standard deviation
(SD)=0.62). Among the 4,118 practices, 3,548 physicians worked in solo-practice and 570
physicians worked in group practices. Based on the final patient cohort, the number of patients
per FP/GP group was, on average, 45 (SD=38), and individual physicians treated an average of
37 patients (SD=26).

Baseline drug use
Baseline use of ACE inhibitors, “other” antihypertensives (i.e. ARBs, beta-blockers, calcium
channel blockers, diuretics) and cholesterol-lowering agents was similar among the intervention
groups (see table 4.2). “Other” antihypertensives were the most commonly prescribed drug class,
with approximately 81% of individuals taking at least one prior to the study. ACE inhibitors and
cholesterol-lowering agents were prescribed to approximately 61% and 63% of patients,
respectively. A treatment regimen consisting of an ACE inhibitor, “other” antihypertensive, and
cholesterol-lowering agent was rather uncommon at baseline, with only one third of patients
receiving prescriptions for all three drug classes.

Drug use at the end of follow-up
One year following PEM mailout, drug use among intervention groups was similar across arms
(see table 4.3). Approximately 84%, 66%, and 61% of individuals were prescribed “other”
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antihypertensives, cholesterol-lowering agents, and ACE inhibitors, respectively. The
combination of an ACE inhibitor, “other” antihypertensive, and cholesterol-lowering agent was
prescribed to approximately 35% of patients.

Table 4.1: Baseline characteristics of physicians in the OPEM diabetes trial.
Variable

Age
(years)
Sex
Canadian
Medical
Graduate
Years in
practice
Visits per
year
Billings
per year
(per CAD
$105)
Practice
location
Rural
practice

Statistic

Mean ± SD

informed
only
N(%)=
1254 (25.3)
52.1 (10.0)

informed +
insert
N(%)=
1228 (24.8)
51.9 (10.1)

informed +
outsert
N(%)=
1255 (25.3)
52.2 (9.9)

informed +
insert + outsert
N(%)=
1220 (24.6)
52.3 (10.3)

Female (%)

260 (20.7)

257 (20.9)

283 (22.5)

300 (24.6)

Yes (%)

951 (75.8)

951 (77.4)

945 (75.3)

941 (77.1)

Mean ± SD

22.0 (9.2)

21.7 (8.8)

22.0 (9.2)

22.2 (9.1)

Mean ± SD

7,142.4
(3,391.6)
2.2 (1.0)

7,096.0
(3,217.0)
2.2 (1.0)

7,229.0
(3,335.8)
2.3 (1.1)

7,075.7
(3,239.0)
2.2 (1.0)

77 (6.1)

99 (8.1)

117 (9.3)

105 (8.6)

151 (12.0)

150 (12.2)

150 (12.0)

169 (13.9)

Mean ± SD

Northern
Ontarioa
(%)
Yesb (%)

SD = standard deviation; “N” is used to denote the total number of individuals in each intervention group.
Brackets within the table represent either SD or an overall percent (see “Statistic” column).
a: Northern Ontario practices defined by a postal code with a forward sortation area beginning with “P”.
b: Rural practices defined by practices in locations with a population of less than 10,000.
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Table54.2: Baseline characteristics of patients in the OPEM diabetes trial.
Variable

Statistic

Age (years)

Sex
Years since
diabetes
diagnosis
Recent
diabetes
diagnosis
(≤2 years)
ACE
inhibitor
use
“Other”
antihypertensive use
Cholesterollowering
agent use
All three
drug classes

66-74 (%)

informed
only
N(%)=
47,499 (25.6)
22,895 (48.4)

informed +
insert
N(%)=
44,845 (24.2)
21,469 (47.9)

informed +
outsert
N(%)=
47,602 (25.7)
22,909 (48.1)

informed +
insert + outsert
N(%)=
45,508 (24.5)
22,096 (48.6)

75-84 (%)

19,603 (41.3)

18,599 (41.5)

19,790 (41.6)

18,914 (41.6)

85+ (%)

4,911 (10.3)

4,777 (10.7)

4,903 (10.3)

4,498 (9.9)

Female
(%)
Mean ±
SD

24,615 (51.8)

23,364 (52.1)

24,879 (52.3)

23,695 (52.1)

7.8 (4.1)

7.8 (4.1)

7.8 (4.1)

7.8 (4.1)

Yes (%)

3,411 (7.2)

3,126 (7.0)

3,488 (7.3)

3,178 (7.0)

Yes (%)

28,836 (60.7)

27,114 (60.5)

28,916 (60.8)

27,568 (60.6)

Yes (%)

38,474 (81.0)

36,224 (80.8)

38,452 (80.8)

36,807 (80.9)

Yes (%)

30,476 (64.2)

28,381 (63.3)

30,213 (63.5)

28,801 (63.3)

Yes (%)

16,065 (33.8)

14,828 (33.1)

15,871 (33.3)

15,161 (33.3)

SD = standard deviation; ACE inhibitor = angiotensin-converting enzyme inhibitor; “N” is used to denote the total
number of individuals in each intervention group. Brackets within the table represent either SD or an overall percent
(see “Statistic” column).

65
Table64.3: Drug use among patients in the OPEM diabetes trial at the end of follow-up.
Variable

Statistic

informed
only

informed +
insert

informed +
outsert

ACE inhibitor
use

Yes (%)

29,026
(61.1)

27,453 (61.2)

29,113 (61.2)

informed +
insert +
outsert
27,783 (61.1)

“Other”
Yes (%)
antihypertensive
use
CholesterolYes (%)
lowering agent
use
All three drug
Yes (%)
classes

39,998
(84.2)

37,634 (83.9)

39,973 (84.0)

38,277 (84.1)

31,789
(66.9)

29,723 (66.3)

31,561 (66.3)

30,186 (66.3)

16,758
(35.3)

15,662 (34.9)

16,561 (34.8)

15,857 (34.8)

ACE inhibitor = angiotensin-converting enzyme inhibitor

Table74.4: Death rates during follow-up.
Variable

Statistic

Died during
follow-up

N (%)

informed
only
2,500 (5.3)

informed +
insert
2,375 (5.3)

informed +
outsert
2,485 (5.2)

informed +
insert + outsert
2,444 (5.4)
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Death rates
Approximately 5% of patients died during follow-up; no meaningful differences were observed
between intervention groups (see table 4.4).

4.3 Primary outcome
The primary outcome is defined as intensification, by drug addition or dose increase, of
medications (ACE inhibitors, “other” antihypertensives (i.e. ARBs, beta-blockers, calcium
channel blockers, diuretics, etc.), and cholesterol-lowering agents) used to control the
cardiovascular complications associated with diabetes.

Intensification rates
Treatment intensification rates were computed for each intervention group by dividing the
number of patients whose treatment regimen intensified (n) by the total number of individuals in
the intervention group (N). Intensification rates were similar across groups, with approximately
46% of patients having experienced a treatment intensification by adding a drug or increasing the
dose of a current drug in all four groups (see table 4.5).

Unadjusted analysis
In the main effects model, the OR for the insert effect was 0.99 (95% CI 0.96 to 1.02), and the
OR for the outsert effect was 1.01 (95% CI 0.98 to 1.04) (see table 4.6).

A model was also fit to include the interaction between the insert and the outsert. The OR for the
interaction was 1.01 (95% CI 0.98 to 1.11), indicating that the effect of the insert was unchanged
by the presence of the outsert (p=0.17). Interaction effects were explored for the remaining
outcomes as per Kahan et al. (2020); however, none of the interactions were statistically
significant with p-values ranging from 0.19 to 0.94. Further analyses are therefore limited to
models with only the main effects of the insert and the outsert.

The intra-cluster correlation coefficient for both the main effects model, and the model including
the interaction term, was 0.023. The variance inflation factor was 2.01, highlighting the need to
account for clustered data in the analyses.
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Table84.5: Intensification rates based on drug additions and dose increases.
INSERT

No
OUTSERT

Yes

No

Yes

46.4%

45.5%

N=47,499

N=44,845

(1,025 clusters)

(1,025 clusters)

46.0%

46.2%

N=47,602

N=45,508

(1,037 clusters)

(1,031 clusters)

N denotes the total number of patients in each intervention group

Table94.6: Unadjusted main effect of the insert and outsert on intensification by drug addition or
dose increase.
Intervention

OR (95% CI)

p value

insert

0.99 (0.96,1.02)

0.50

outsert

1.01 (0.98,1.04)

0.74
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Adjusted analysis
Neither a statistically significant insert effect, nor an outsert effect, were observed after adjusting
for the following physician characteristics: physician age, sex, Canadian medical graduate,
practice location, rural practice, total general patient visits per year, total billings per year, and
years in practice (see table 4.7). Female physicians were more likely to intensify their patient’s
treatment regimens than were male physicians (OR 1.08, 95% CI 1.03 to 1.12). Moreover,
physicians who graduated from Canadian medical schools were less likely to intensify their
patient’s treatment regimens compared to those who graduated from international medical
schools (OR 0.93, 95% CI 0.89 to 0.97). For every ten additional years that a physician had been
in practice, their likelihood of complying with guideline recommendations decreased (OR 0.96,
95% CI 0.91 to 0.99).
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Table104.7: Main effects model adjusted for physician characteristics.
Variable

OR (95% CI)

p value

Insert

0.99 (0.96, 1.02)

0.58

Outsert

1.00 (0.97, 1.03)

0.77

Physician age
(per 10 years)

1.00 (0.97, 1.04)

0.94

Sex
(reference is male)

1.08 (1.03, 1.12)

<0.0001

Canadian medical graduate
(reference is no)

0.93 (0.89, 0.97)

<0.0001

Years in practice
(per 10 years)

0.96 (0.91, 0.99)

0.03

Total visits
(per 100 visits)

1.00 (1.00, 1.00)

0.23

Total billings
(per $10,000)

1.00 (1.00, 1.00)

0.10

Practice location
(reference is Southern)

0.97 (0.91, 1.03)

0.32

Rural practice
(reference is no)

0.99 (0.94, 1.03)

0.55

70

4.3.1 Subgroup analysis
Intensification rates
Intensification rates among patients with recent diabetes diagnoses were similar to those
observed in patients with non-recent diagnoses (see tables 4.8 and 4.9, respectively).
Approximately 46% of patients in each of the four treatment groups experienced an
intensification of their treatment regimen; this rate did not appear to be affected by the recency of
diabetes diagnosis.

Interaction effect
Neither the interaction between the insert and the recency of diabetes diagnosis, nor the
interaction between the outsert and the recency of diabetes diagnosis, were statistically
significant (p=0.77 and p=0.82, respectively). Thus, a logistic regression analysis was not
justified.

Table114.8: Intensification rates among patients diagnosed with diabetes on January 14th, 2003 or
later (recent diagnoses).
INSERT
No
46.1%

Yes
45.4%

No
OUTSERT

N=3,411
46.0%

N=3,126
46.5%

N=3,488

N=3,178

Yes

Table124.9: Intensification rates among patients diagnosed with diabetes prior to January 14th,
2003 (non-recent diagnoses).
INSERT
No
46.4%

Yes
45.5%

No
OUTSERT

N=44,088
46.0%

N=41,719
46.2%

N=44,114

N=42,330

Yes
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4.3.2 Sensitivity analyses
The trial had two arms (intervention, and control) and four groups (control, insert, outsert, and
insert+outsert). The first sensitivity analysis identified patients who switched from the control
arm to any intervention arm (or vice versa), and the second sensitivity analysis identified patients
who made any type of switch between groups (i.e. from insert to outsert group, from outsert to
insert+outsert group, from control group to insert group, etc.).
Switching between arms
Throughout the follow-up period, 4,430 patients (9.3%) in the control group switched physicians
and moved to a physician in an intervention arm of the trial. Conversely, 1,554 patients (3.5%) in
the insert group, 1,665 patients (3.5%) in the outsert group, and 1,518 patients (3.3%) in the
insert+outsert group were seen by a control physician during the follow-up period. A total of
176,287 patients stayed in their original intervention group and thus remained in the per-protocol
analysis.

Intensification rates among patients who stayed in their original treatment arm differed slightly
across intervention groups, with the control group seeing a marginally higher rate of
intensification than did the intervention groups (see table 4.10). The OR for the insert effect was
0.97 (95% CI 0.94 to 0.99), and the OR for the outsert effect was 0.98 (95% CI 0.96 to 1.01) (see
table 4.11).
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Table134.10: Intensification rates among patients who remained in their original treatment arm.
INSERT
No
47.8%

Yes
46.0%

No
OUTSERT

N=43,069
46.6%

N=43,291
46.7%

N=45,937

N=43,990

Yes

Table144.11: Unadjusted effect of the insert and outsert on intensification rates among patients
who stayed in their original intervention arm.
Intervention

OR (95% CI)

p value

insert

0.97 (0.94,0.99)

0.03

outsert

0.98 (0.96,1.01)

0.29
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Switching between groups
Throughout the follow-up period, 23,455 patients (12.7%) saw a physician who belonged to a
different treatment group than the group to which they were assigned. The frequency of switches
was similar among intervention groups; 5,821 patients (12.3%) in the control group, 5,719
patients (12.8%) in the insert group, 6,244 patients (13.1%) in the outsert group, and 5,671
patients (12.5%) in the insert+outsert group switched to a new group in the one year following
the PEM mailout. Thus, 161,999 patients were included in the per-protocol analysis.

Treatment intensification rates among the patients who remained in their original intervention
group were similar across groups (see table 4.12). The frequency of intensification was lowest in
the insert only group, but the difference was trivial. The ORs for the insert and outsert effects
were 0.99 (95% CI 0.96 to 1.02) and 1.01 (95% CI 0.98 to 1.04), respectively (see table 4.13).

Table154.12: Intensification rates among patients who remained in their original treatment group.
INSERT
No
48.4%

Yes
47.4%

No
OUTSERT

N=41,678
48.2%

N=39,126
48.1%

N=41,358

N=39,837

Yes

Table164.13: Unadjusted effect of the insert and outsert on intensification rates among patients
who stayed in their original intervention group.
Intervention

OR (95% CI)

p value

insert

0.99 (0.96,1.02)

0.36

outsert

1.01 (0.98,1.04)

0.63
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4.4 Secondary outcomes
4.4.1 Including drug switches in the definition of treatment intensification
Intensification rates
The frequency of patients who experienced a treatment intensification based on drug additions,
dose increases, or drug switches was comparable across intervention groups (see table 4.14).
Intensification rates based on additions, dose increases, and switches (secondary outcome) were,
on average, slightly higher (approximately 2%) than those based on additions and dose increases
alone (primary outcome) (see table 4.5).

Unadjusted analysis
The OR for the insert effect was 0.99 (95% CI 0.96 to 1.02), and the OR for the outsert effect
was 1.01 (95% CI 0.98 to 1.04) (see table 4.15).

Table174.14: Intensification rates based on drug additions, dose increases, and drug switches.
INSERT
No
48.7%

Yes
47.9%

No
OUTSERT

N=47,499
48.4%

N=44,845
48.7%

N=47,602

N=45,508

Yes

Table184.15: Unadjusted effect of the insert and outsert on intensification by addition, dose
increase, or switch.
Intervention

OR (95% CI)

p value

insert

0.99 (0.96,1.02)

0.64

outsert

1.01 (0.98,1.04)

0.60

75

4.4.2 Intensification within individual drug classes
ACE inhibitors
Approximately 12% of patients experienced treatment intensification by the addition of an ACE
inhibitor, or the increase in dose of a current ACE inhibitor; no substantial differences were
observed across intervention groups (see table 4.16). There was no difference in the odds of
intensification by ACE inhibitor between those who received the insert and those who did not
(OR 1.00, 95% CI 0.96 to 1.04) (see table 4.17). Similarly, the odds of intensification by ACE
inhibitor were the same for those who received the outsert and those who did not (OR 1.00, 95%
CI 0.96 to 1.04), suggesting no effect.

Table194.16: Intensification rates for the addition or dose increase of ACE inhibitors.
INSERT
No
11.9%

Yes
12.0%

No
OUTSERT

N=47,499
12.1%

N=44,845
11.9%

N=47,602

N=45,508

Yes

Table204.17: Unadjusted effect of the insert and outsert on intensification by the addition of a new
ACE inhibitor, or the increase in dose of a current ACE inhibitor.
Intervention

OR (95% CI)

p value

insert

1.00 (0.96,1.04)

0.99

outsert

1.00 (0.96,1.04)

0.97
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“Other” antihypertensives
Approximately 32% of patients in all four intervention groups experienced treatment
intensification by the addition of a new antihypertensive (excluding ACE inhibitors), or the
increase in dose of a current antihypertensive (see table 4.18). The ORs for the insert effect and
the outsert effect on prescriptions of “other” antihypertensives were 0.99 (95% CI 0.97 to 1.02)
and 1.01 (95% CI 0.99 to 1.04), respectively (see table 4.19), again suggesting no effect.

Table214.18: Intensification rates for the addition or dose increase of antihypertensives.
INSERT
No
32.0%

Yes
31.6%

No
OUTSERT

N=47,499
32.1%

N=44,845
32.2%

N=47,602

N=45,508

Yes

Table224.19: Unadjusted effect of the insert and outsert on intensification by the addition of a new
antihypertensive agent, or the increase in dose of a current antihypertensive agent.
Intervention

OR (95% CI)

p value

insert

0.99 (0.97,1.02)

0.68

outsert

1.01 (0.99,1.04)

0.35
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Cholesterol-lowering agents
Treatment intensification by the addition of a new cholesterol-lowering agent or the increase in
dose of a current cholesterol-lowering agent occurred, on average, in 13% of patients; no
meaningful differences were observed between intervention groups (see table 4.20). The ORs for
the effect of the insert and outsert on intensification by cholesterol-lowering agents were 0.99
(95% CI 0.95 to 1.03) and 1.01 (95% CI 0.97 to 1.06), respectively (see table 4.21), suggesting
no effect.

Table234.20: Intensification rates for the addition or dose increase of cholesterol-lowering agents.
INSERT
No
13.0%

Yes
12.8%

No
OUTSERT

N=47,499
13.0%

N=44,845
13.0%

N=47,602

N=45,508

Yes

Table244.21: Unadjusted effect of the insert and outsert on intensification by the addition of a new
cholesterol-lowering agent, or the increase in dose of a current cholesterol-lowering agent.
Intervention

OR (95% CI)

p value

insert

0.99 (0.95,1.03)

0.66

outsert

1.01 (0.97,1.06)

0.56
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Chapter 5
5

Discussion

This chapter begins with a discussion of the key findings in section 5.1, including both a
summary and interpretation of the results. The strengths and the limitations of the study are
discussed in sections 5.2 and 5.3, respectively. Directions for future research are provided in
section 5.4, followed by the conclusions in section 5.5.

5.1 Key Findings
5.1.1 Summary of findings
The aim of the OPEM trial was to determine whether PEMs can successfully influence
physicians to improve adherence to guideline recommendations for diabetes care through
treatment intensification. Owing to the factorial design, the trial was able to simultaneously
evaluate the effectiveness of two distinct PEMs: a two-page insert, and a short, directive outsert.
Based on previous studies, it was determined that an absolute improvement as small as 5% is
clinically significant (Zwarenstein et al., 2007). Considering the large sample size, a 5%
improvement in prescribing rates would mean that a substantial number of Ontarians would, in
theory, live healthier lives due to their improved treatment regimens.

Baseline characteristics of both patients and physicians were well balanced among the four
groups. Moreover, there were no meaningful differences in baseline use of ACE inhibitors,
“other” antihypertensives (i.e. ARBs, beta-blockers, calcium channel blockers, diuretics, etc.),
and cholesterol-lowering agents among patients in all four groups. Death rates were also
balanced between the groups and approximately equal to 5%, which is consistent with death
rates among Ontarians aged 66 and above between 2004 and 2006 (Statistics Canada, 2020).
During this time, death rates for Ontarians aged 66-74 and 75-84, the two most common age
groups for trial patients, were between 1.2-2.6%, and 2.9-7.4%, respectively (Statistics Canada,
2020).

Intensification rates during the one-year follow-up were approximately 46%; these rates did not
meaningfully differ (neither statistically, nor clinically) between groups. In regression analyses,
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it was found that the OR for the insert effect was 0.99 (95% CI 0.96 to 1.02), while the OR for
the outsert effect was 1.01 (95% CI 0.98 to 1.04). In light of the statistically not significant
findings, we had insufficient evidence to conclude that intensification rates among physicians
who received the insert or outsert were any different than among those who did not.

While the trial was not powered to study the interaction between the insert and the outsert, we
completed this analysis for exploratory purposes. It was determined that the effect of the insert
was not significantly altered by the presence of the outsert, and vice-versa (p=0.17).

We were interested in testing whether the intervention effect differed in patients with recent
diabetes diagnoses (≤ 2 years) compared to patients who had been living with the disease for a
number of years. Thus, a subgroup analysis was planned. Neither the interaction between the
insert and the recency of diagnosis, nor the interaction between the outsert and recency of
diabetes, were statistically significant (p=0.77 and p=0.82, respectively). A subgroup analysis
using a logistic regression model was therefore not carried out, as it would not provide any
meaningful information. Accordingly, it is reasonable to report the main effects of the insert and
the outsert without considering the recency of diabetes diagnosis.

The characteristics of physicians that influenced their likelihood of changing practice were
explored. Three variables were found to have small, but statistically significant effects on
intensification among physicians. Female physicians were more likely to intensify their patient’s
treatment regimens than were male physicians (OR 1.08, 95% CI 1.03 to 1.12). Moreover, a
physician’s likelihood of adhering to guideline recommendations in response to PEMs decreased
for every ten years that they were in practice (OR 0.96, 95% CI 0.92 to 0.99). Lastly, Canadiantrained physicians were less likely to intensify their patient’s treatment regimens than were
internationally trained physicians (OR 0.93, 95% CI 0.89 to 0.97). Nevertheless, all three ORs
were very close to one, suggesting that, while statistically significant, the effect of the
aforementioned physician characteristics on treatment intensification is minimal and is unlikely
to translate into clinically meaningful effects. We note that the relationship between these
physician characteristics and the likelihood of engaging in behavior change (specifically,
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treatment intensification) are fixed phenomena and it is difficult to see how an intervention, such
as a PEM, could target them.

Two sensitivity analyses were run. First, the primary outcome was analyzed in the 176,287
patients who did not switch between arms throughout the study period. Intensification rates were
higher in the per-protocol population, albeit marginally so, than in the ITT population. The OR
for the insert effect was 0.97 (95% CI 0.94 to 0.99), suggesting that physicians who received the
insert were less likely to intensify than were those who did not receive the insert, a result
opposite to the one we intended to find. However, while this result was statistically significant
(p=0.03), it was of little clinical significance since it was less than the smallest effect size (5%)
that we regarded as clinically important. Moreover, the OR for the outsert effect was 0.98 (95%
CI 0.96 to 1.01), again suggesting that the effect of the outsert was to decrease intensification
rates; however, this result was neither of statistical significance (p=0.29), nor of clinical
significance. The second sensitivity analysis was conducted to ascertain whether the results of
the primary outcome were significantly altered by patients who switched between groups.
Among the 161,999 patients who remained in their original treatment group, neither a
statistically significant insert effect (OR 0.99, 95% CI 0.96 to 1.02), nor a statistically significant
outsert effect (OR 1.01, 95% CI 0.98 to 1.04), were detected.

The results, taken together, suggest that PEMs do not lead to statistically significant, nor
clinically important, improvements in adherence to guideline recommendations for diabetes care
by way of treatment intensification. Moreover, the absolute effect of both the insert and outsert
were near zero and thus well below the 5% minimally clinically important improvement that we
intended to find.

5.1.2 Interpretation of findings
The finding that PEMs do not successfully influence provider behavior is not unusual. In fact,
this result has been reported by many researchers previously, although never in as large a trial
(Bero et al., 1998; Grol & Grimshaw, 2003). Moreover, these results are not surprising in light of
the findings from the previously published OPEM trials (Zwarenstein et al., 2014; Zwarenstein et
al., 2016).
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While the exact reason for the failure of the PEMs to lead to intensification remains unclear, we
offer several hypotheses below.

Pre-intervention prescribing rates
The rate of ACE inhibitor use among Ontarian’s with diabetes was measured around the time the
OPEM programme was developed (Zwarenstein et al., 2007). Pilot data revealed that only 36%
of individuals were taking an ACE inhibitor (Zwarenstein et al., 2007). However, the rate of
ACE inhibitor use among the trial patients was measured one year prior to the PEM mailout and
was found to be approximately 60% across all groups (see table 4.2). The reason for this marked
increase in prescribing rates is unclear, but may offer an explanation for the failure of PEMs to
lead to treatment intensification. While a substantial number of individuals were still not
prescribed an ACE inhibitor at baseline, the number requiring treatment intensification using an
ACE inhibitor was much lower than anticipated and may have reached its ceiling. Moreover,
baseline prescribing rates of “other” antihypertensives was over 80% (see table 4.2), offering
little room for improvement. Thus, it is possible that, between the time when the pilot research
was conducted and baseline data were collected, physicians were encouraged, by other sources,
to increase prescribing of the study drugs. As a result, when the PEMs were mailed, physicians
may have assumed that they already intensified their patient’s treatment regimens enough, and
that the recommendations outlined in the PEMs no longer applied to them.

informed
A survey conducted in 1997 revealed that Ontario physicians considered informed to be a useful
source of clinical information (Kelsall, 2005). However, eight years later, when the PEMs were
delivered, informed readership may have declined and the way in which informed was mailed to
the entire FP/GP group for the OPEM programme may simply not have engaged these doctors as
readers. Thus, the failure of PEMs to lead to treatment intensification may not be attributed to the
PEMs themselves, but rather to the failure of physicians to open and read the journal.
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Information seeking behaviors of physicians
Despite widely available clinical practice guidelines, the evidence-to-practice gaps suggest that
health care providers do not uniformly follow these recommendations. Accordingly, researchers
have attempted to study the information-seeking behaviours of health care providers to determine
the most efficient ways to deliver educational materials. Numerous studies have revealed that
health care providers do not pursue answers to many of their clinical queries (Ely et al., 1999;
Dawes & Sampson, 2003; Coumou & Meijman, 2006; Clarke et al., 2013). While the percentage
of questions that providers sought answers to varied in each of the studies, it ranged from 23% to
57% of all potential questions (Ely et al., 1999; Dawes & Sampson, 2003; Coumou & Meijman,
2006; Clarke et al., 2013). Factors that prompted information seeking behaviors included the
convenience of access, reliability of sources, urgency of the problem, habit, and whether or not
the provider believed a definitive answer existed (Ely et al, 1999; Dawes & Sampson, 2003). The
most commonly cited reasons for not seeking answers were a shortage of time and information
overflow (Dawes & Sampson, 2003; Coumou & Meijman, 2006; Davies, 2007; Clarke et al.,
2013).

Near the time of the OPEM programme, research showed that primary care providers continued
to seek answers to their clinical queries by consulting with colleagues and searching in textbooks
(Coumou & Meijman, 2006). Paper sources have been known to provide readily available and
applicable information, thus providing a solution to the barrier of time (Dawes & Sampson,
2003). Accordingly, in 2003, researchers predicted that the proportion of physicians who utilized
paper sources was between 50-80% (Dawes & Sampson, 2003). As a result, one might expect
that the OPEM physicians would be inclined to read a PEM. However, paper sources have also
been criticized for being outdated and for not providing the most appropriate answer to clinical
queries (Clarke et al., 2013). With the increased availability of computers and internet access,
electronic sources may have been a more trusted information source for OPEM physicians.
While studies on information seeking behavior of Ontario physicians is lacking, research in other
countries suggests that, at the time of the trial, electronic databases, namely MEDLINE, were
gaining prominence (Dawes & Sampson, 2003; Coumou & Meijman, 2006). Thus, it is possible
that PEMs were not well received by OPEM physicians due to the shift towards consuming
electronic information for clinical decision making.
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The struggle of unlearning
To change clinical practice, physicians must replace routine, outdated operations with new,
evidence-based practices. While adding to their knowledge base can be a simpler undertaking,
dismissing current practices has been consistently found to be challenging (Rushmer & Davies,
2004; Gupta et al., 2017). The process of change disrupts the status quo equilibrium, causing
physicians to be uncertain about practices they considered to be “certain” (Gupta et al., 2017).
Physicians included in the study had been practicing as a FP/GP for, on average, 22 years (see
table 4.1). As a result, they may have adopted standard prescribing practices for individuals with
diabetes over the years and were thus unwilling to implement a change to multiple drug classes
in response to the PEM.

Failure to account for specialist physicians
We focused solely on prescriptions that were written by FP/GPs, despite knowing that a subset of
patients received care from diabetes specialists. In 2005, there were 128 Endocrinologists
practicing in Ontario (Canadian Medical Association, 2005). Many of these physicians also treat
patients with non-diabetes endocrine disorders; thus, the number of individuals who had their
diabetes managed solely by an Endocrinologist was likely very low. Accordingly, the inclusion
of individuals whose diabetes was managed by an Endocrinologist, rather than a FP/GP, is
unlikely to have largely influenced our intervention effect.

5.2 Strengths
Study design
The 2x2 factorial design allowed us to test two versions of a PEM at once: an insert, and an
outsert. This allowed us to make recommendations about PEMs in general, but also about
specific design choices. Moreover, random assignment ensured that baseline characteristics of
the physicians and patients were well-balanced, on average, among the intervention groups (see
tables 4.1 and 4.2).

All study data came from databases held at ICES. Without the need for primary data collection,
the costs associated with this study were low (in fact, all three OPEM trials, randomizing
hundreds of thousands of patients and thousands of physicians were completed on a budget of
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less than $300,000 CAD). Moreover, though the costs associated with developing, printing, and
mailing the PEMs were not recorded, previous research suggests that the costs to develop and
implement PEMs are significantly lower than other KT intervention strategies (Mewes et al.,
2017).

Directly answers literature demands
The debate surrounding the effectiveness of PEMs is ongoing. The most recent systematic
review suggests that, to determine the true benefit of PEMs, high-quality studies must be
undertaken that clearly describe the intervention and are adequately powered to detect small
treatment effects (Grudniewicz et al., 2015 a). Our study directly meets these requirements. We
clearly outlined the professionals who contributed to the design of the PEMs, provided a detailed
description of the PEM layout, and included pictures of the exact PEMs that were mailed (see
Appendix figures 3-4). Moreover, our large sample size ensured that we had adequate power to
detect an effect as small as 5% (see Zwarenstein et al., 2007 for more details). Accordingly, our
study provides concrete evidence for the effectiveness of PEMs, and the findings may be
included in future systematic reviews investigating the benefit of PEMs.

5.3 Limitations
The use of administrative data
The reliance on administrative data to build our cohort and to ascertain outcomes presented as a
limitation to this study for three reasons. Firstly, the only database available to monitor
prescription patterns is ODB, a program that, at the time of the trial, covered prescription drugs
for the following individuals: those 65 and older, on social assistance, receiving benefits from
Ontario’s Assistance for Children with Severe Disabilities program, receiving care under the
Home Care Program, eligible under the Trillium Drug Program, and residing in Long-Term Care
facilities and in Homes for Special Care (HIV & AIDS Legal Clinic Ontario, 2020). Since the
majority of individuals eligible for ODB are 65 and older, we chose to limit our study population
to those 66 and older (an additional year to allow for baseline measurements). However, the
recommendations outlined in the PEMs are not unique to seniors, but rather apply to all
individuals above 50 living with diabetes. As a result, we are unable to ascertain whether the
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intervention effects are consistent across all age groups; thus, the generalizability of our results
are limited to populations of individuals with diabetes aged 66 and above.

Moreover, without access to any clinical documentation on the actual wellbeing and BP and
cholesterol levels of individual patients, we were unable to differentiate between those who had
well-controlled diabetes, and those who required treatment intensification. Despite national and
provincial statistics that suggest that diabetes is, on average, poorly managed, we should expect
that some patients are taking the appropriate medications to manage their disease and/or that
their clinicians consider it unwise to intensify their treatment because of reasons other than their
diabetes. Obtaining BP and cholesterol measurements would have allowed us to exclude those
patients who would not benefit from treatment intensification. Instead, those who did not
undergo treatment intensification throughout the study period were classified as “failures”.
Furthermore, we were unable to identify patients who had allergies or contraindications to any of
the study drugs; therefore, they were regarded as “failures” in our study, despite being ineligible
to receive the drugs in routine practice. However, as a consequence of randomization, we expect
that individuals who were not in need of intensification by the study drugs were equally
distributed between trial arms; thus, this is unlikely to have meaningfully distorted our findings.

Lastly, relying solely on administrative data necessitated that a large assumption be made about
our population. We assumed that all FP/GPs received the PEMs, read them, and subsequently
decided whether or not to implement the guideline recommendations in their practice. As a
result, all FP/GPs who were mailed a PEM and who met our inclusion criteria were included in
our analysis. However, it is possible that the PEM was not delivered to the proper address, or that
the FP/GP discarded the journal without reading the PEM. Additionally, we are unable to
distinguish between a FP/GPs decision to ignore the PEM from a patient’s resistance to
implementing the change. Another assumption was that the patients were taking the drugs they
were prescribed.

Generalizability
While the trial was designed with a pragmatic intention, the eligibility criteria proved to be rather
strict. According to the Canadian Medical Association (2005), there were 10,545 family
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physicians practicing in Ontario in 2005. After excluding those not deemed to be in “active
practice”, our intervention was delivered to 5,178 physicians (see figure 4.1). Thus, while the
sample size was still remarkably high, the intervention did not reach as many physicians, and
thus patients, as anticipated. The results are therefore generalizable to Ontario FP/GPs who billed
at least $50,000 in 2004, and who prescribed medications to at least 100 seniors (≥66 years old)
in at least 10 months between August 2003 and July 2004. Over 3,000 physicians were excluded
on the basis of not treating an adequate number of individuals aged 66 and above (see figure
4.1). It is possible that physicians who treat a smaller number of individuals 66 and above have
less experience with diabetes care and would therefore benefit from the receipt of PEMs.
However, these physicians were not included in the study population and, as a result, the findings
may not be generalizable to all Ontario FP/GPs.

Use of the ODB database to ascertain outcome status
The ODB database only contains prescriptions that have been dispensed. Thus, since our
intervention is targeting physician behavior change, it is possible that the intervention effect was
diluted by patients who received a prescription for one of the study drugs, but failed to get it
dispensed. Nevertheless, we expect that the proportion of patients who failed to fill their
prescriptions would be balanced among the four groups as a consequence of randomization; thus,
the intervention effect is unlikely to biased.

Time period
A discussion of the limitations would not be complete without acknowledging the timeframe in
which the study was carried out. The PEMs were mailed in January of 2005, and the outcome
measurement took place between 2005 and 2006. Estimates at the time of the trial suggested that
prescriptions for all of ACE inhibitors, “other” antihypertensives, and cholesterol-lowering
agents were at least 30% below guideline recommendations (Zwarenstein et al., 2007). There is
wonder whether or not the results from the present study are generalizable to today’s
environment. Despite a lack of recent Canadian statistics, we have reason to believe that care for
diabetes remains below standard. The 2018 Diabetes Clinical Practice Guidelines still declare
that diabetes-related cardiovascular complications are responsible for the greatest burden of
disability and death among individuals with diabetes (Diabetes Canada, 2018b). Accordingly,
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Diabetes Canada strongly recommends that individuals are treated with appropriate medications
to manage these risks, including antihypertensives and cholesterol-lowering agents (Diabetes
Canada, 2018b). Moreover, recent estimates from the U.S. revealed that care has not improved in
spite of major advances and standardized treatment strategies (Kazemian et al., 2019). It has
been previously shown that diabetes treatment targets are comparable in Canada and the U.S.
despite different methods of care delivery, suggesting that this poor treatment is likely also
observable in Canada (Booth et al., 2002). Thus, while we have several reasons to believe that
care for diabetes continues to be poor in Ontario, we do not have concrete evidence that the
prescription rates for the study drugs are as poor today, and in need of intensification, as they
were at the time of the trial.

Fifteen years later, we might expect that healthcare providers use alternate sources to seek
answers to their clinical queries. While the shift from paper-based medical records to electronicbased systems has been gradual, in 2019, 94.3% of FP/GP’s in Ontario reported using some form
of electronic tool for tasks such as specialist referrals, ordering lab tests, or accessing patient
information systems, in their practice (Canadian Medical Association, 2019a). Simultaneously,
physicians have increasingly relied on internet sources, such as MEDLINE, the Cochrane
Library, and Google, to assist in decision-making (Clarke et al., 2013). PEMs continue to be
utilized as a knowledge translation tool today; however, one wonders whether electronic sources
have a greater capacity to alter physician prescribing practices than do printed materials.

Primary outcome definition
The primary outcome definition, as described in section 3.6.2, considers either a drug addition or
a dose increase as treatment intensification. While we expect that the majority of individuals refilled their prescription once their previous one was complete, it is possible that some individuals
received a new prescription before finishing their previous one. For example, an individual may
have seen their FP/GP for reasons other than diabetes management shortly before their diabetes
prescription was to run out. The FP/GP may have, for convenience’s sake, written a new
prescription for that individual to be taken once the previous course was complete. In these
situations, it will appear that the physician intensified the individual’s treatment regimen by
adding a drug, even though the two drugs were never taken simultaneously. Even if the FP/GP
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made a medication switch, which we chose to exclude from the primary outcome, this was
erroneously captured as a medication addition in the primary outcome definition in these
scenarios. That being said, we expect the individuals who re-filled their prescriptions early, if
there were any, to be balanced across the four groups due to randomization; therefore, the
treatment effect is unlikely to be biased.

Competing risks challenges
All analyses were carried out using logistic regression models estimated using GEE, as described
in the OPEM protocol (Zwarenstein et al., 2007). While this model accounts for clustered data, it
fails to take into account the competing risk of death. The model assumes that patients can
experience one of two outcomes after one year of follow-up: a treatment intensification, or no
intensification. Thus, patients who died during the follow-up period without experiencing a
treatment intensification were placed in the “no intensification” group. However, once these
patients died, for the remainder of the follow-up period they had no opportunity to experience a
treatment intensification. A more complex analysis of the cumulative incidence of intensification
while taking into account the competing risk of death may have been more appropriate
(Anderson et al., 2012). That being said, the death rates among patients in the trial were low (see
table 4.4). Moreover, death rates were balanced across groups, and appear to be representative of
death rates among Ontario seniors at the time of the trial. Accordingly, the models used in the
analyses are reasonable and the estimates of the intervention effect are likely valid.

5.4 Direction for future research
Despite notable efforts to attenuate the evidence-to-practice gap, prescription drug use for
diabetes care continues to fall short of guideline recommendations today. This study revealed
that PEMs did not successfully influence FP/GP physicians to intensify their patients’ treatment
regimens. However, a limitation of the study, as discussed in section 5.3, is the absence of any
clinical information on the individual patients. Future studies could link a larger number of
databases to include clinical data, such as BP and cholesterol measurements, to limit the patient
sample to only those in need of treatment intensification. In addition, since the vast majority of
physicians have shifted to the use of electronic medical records, it is of interest to explore
whether an electronic version of a PEM would lead to greater improvements in adherence to
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guideline recommendations than did the mailed PEM. The electronic recommendations would
presumably be sent via email or through online portals, and would need to be designed with
meticulous detail to overcome the barriers associated with electronic information sharing. Lastly,
Primary Care Practice Reports have the potential to influence physician prescribing practices.
These confidential reports, developed by Ontario Health Quality and ICES, are designed to
encourage physicians to provide high-quality care according to guideline recommendations by
providing them with an overview of their current care patterns in relation to their peers (Health
Quality Ontario, 2019). At present, the diabetes section of the report provides information on
HbA1c testing, retinal screening, and statin prescriptions (Health Quality Ontario, 2019). These
reports could be updated to provide additional information on prescribing patterns of ACE
inhibitors and “other” antihypertensives. While the receipt of these reports is currently voluntary,
future studies may consider sending these reports, either by mail or electronically, to all Ontario
FP/GPs to investigate whether this KT strategy is effective at attenuating the evidence-topractice gap. The PEMs delivered in this study provided broad recommendations for prescribing
patterns for all physicians. A tailored report, like the Primary Care Practice Report, may
encourage physician compliance, as they are provided with clear examples of areas that need
improvement in their individual practice.

5.5 Conclusion
Overall, it was found that PEMs alone, whether long and narrative and inside a journal (insert) or
whether brief and action focused attached to the cover (outsert), are not effective at changing
physician prescribing behaviours for individuals with diabetes aged 66 and above. Despite their
low costs and wide reach, PEMs, in their present form, are not an effective KT strategy in
primary care in Ontario for diabetes intensification and should not be utilized as a knowledge
translation strategy. Given the context of multiple studies of a range of PEM interventions for a
number of evidence-to-practice gaps, this may be a generalized failure of PEMs. Further research
is warranted to investigate the effect of other knowledge translation strategies targeted at
physicians to narrow the evidence-to-practice gap for the management of diabetes complications.
In this modern era of electronic health records, one might think of electronic interventions such
as point of care reminders, on screen prompts, and electronic audit and feedback (Shojania et al.,
2009; Tuti et al., 2017).
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